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The International Regulation of Genetically Modifi ed 
Organisms: Importing Caution Into the 
U.S. Food Supply
DEBRA M. STRAUSS*
I. INTRODUCTION
Biotechnology is big business.1 As such, the use of biotechnology to engineer plants, 
and the regulation of the resulting food crops, involves economic and trade issues, as 
well as science and health issues.2
Through modern biotechnology, selected individual genes are transferred from one 
organism into another, sometimes between nonrelated species, using recombinant DNA 
(rDNA) methods.3 The genetically modifi ed organisms (GMOs) that are created as GM 
plants then produce GM foods.4 The fi rst GM crop—the GM tomato—was sold in the 
market in 1994,5 and genetically modifi ed products have been commercially available 
in the United States since 1995.6 Genes derived from a bacterium in the soil, Bacillus 
thuringiensis (Bt), have been inserted into crops to promote resistance to certain insects, 
producing Bt-corn, Bt-cotton, Bt-potato, Bt-rice, and Bt-tomato. Glyphosate-tolerant 
soybeans (e.g., Roundup Ready® by Monsanto) contain a gene that protects them from 
the herbicide glyphosate so that the fi elds can be sprayed with the herbicide, thus killing 
the weeds while leaving the soybeans standing. Herbicide-resistant varieties of canola, 
cotton, corn, radicchio, rice, and sugar beet also are on the market. The United States 
has approved virus-resistant varieties of papaya, potato, and squash, along with tomato 
* Debra Strauss is an Assistant Professor of Business Law, Fairfi eld University, Charles F. Dolan School 
of Business, Fairfi eld, Conn. She received her B.A. from Cornell University and her J.D. from Yale Law 
School. Professor Strauss, a former Food and Drug Law Institute Scholar, currently teaches international 
business law.
1 Biotechnology is one of the fastest-growing sectors of the U.S. economy. The interests of global 
business are substantial as well—71% of all agrobiotechology patents are owned by the top fi ve companies 
in the area: Pharmacia (now owned by Pfi zer Inc.) (21%, 287 patents), DuPont (20%, 279 patents), Syngenta 
(13%, 173 patents), Dow (11%, 157 patents), and Aventis (6%, 77 patents). Tzu-Ming Pan, Current Status 
and Detection of Genetically Modifi ed Organism, 10 J. FOOD & DRUG ANALYSIS 229, 230 (2002) (citing ETC 
Group, Globalization Inc. Communique #71 (2001)).
2 For background on this issue, including additional statistics, see Debra M. Strauss, Genetically Modi-
fi ed Organisms in Food: A Model of Labeling and Monitoring With Positive Implications for International 
Trade, 40 INT’L LAW. 95 (2006). Some of the points that will be discussed here expand upon points that were 
raised in this article.
3 BINAS Online, Facts on GMOs in the EU, http://binas.unido.org/binas/regs.php (last visited Mar. 
16, 2006) [hereinafter Facts on GMOs in the EU]; NATIONAL RESEARCH COUNCIL, SAFETY OF GENETICALLY 
ENGINEERED FOODS: APPROACHES TO ASSESSING UNINTENDED HEALTH EFFECTS (July 2004) [hereinafter NRC 
SAFETY], available at http://www.nap.edu/html/ge_foods/ge-foods-reportbrief.pdf (“Recombinant DNA 
methods enable the insertion of a gene or gene sequence in an exact place in the DNA of the new host, thus 
producing a targeted result.”).
4 World Health Organization (WHO), Food Safety, 20 Questions on Genetically Modifi ed (GM) Foods, 
http://www.who.int/foodsafety/publications/biotech/20questions/en/index.html (last visited May 11, 2006) 
[hereinafter WHO, Questions on GM Foods].
5 Pan, supra note 1, at 230 (citing ISAA ANNUAL REPORT 2002).
6 In 1990, FDA approved the fi rst biotechnology food product for the U.S. market—chymosin, a food-
processing enzyme produced by GM bacteria. Chymosin is the active enzyme in rennet, a milk-clotting agent 
used to make cheese. Traditionally, rennet was obtained from calf stomach linings. U.S. FOOD AND DRUG 
ADMINISTRATION (FDA), SAFETY ASSURANCE OF FOODS DERIVED BY MODERN BIOTECHNOLOGY IN THE UNITED STATES 
(July 1996), available at http://www.cfsan.fda.gov/~lrd/biojap96.html.
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and cantaloupe, which contain a gene that slows the ripening process to allow fruit to 
ripen longer on the vine.7
Worldwide, GMOs have grown exponentially; the total area of biotech crops increased 
thirty times between 1996 and 2001. As global plantings of biotech crops grew to about 
200 million acres in 2004, about two-thirds of the plantings took place in the United 
States.8 More than 40% of the corn, more than 50% of the cotton, and more than 80% 
of soybean acres planted in the United States have been genetically modifi ed. As a 
conservative estimate, at least 70% of food products in U.S. supermarkets—boxed cere-
als, other grain products, frozen dinners, cooking oils, and more—contain GMOs.9 The 
Grocery Manufacturers of America (GMA) estimates that 75% of all processed foods 
in the United States contain a GM ingredient, including almost every product with a 
corn or soy ingredient and some containing canola or cottonseed oil.10
Yet, obstacles from abroad have closed the international market not only for foods 
genetically engineered in the United States, but also for a signifi cant portion of all U.S. 
produce.11 This ban has occurred in part because, unlike the European community, the 
United States does not segregate, label, or treat GM foods differently from traditional 
foods. The divergent approaches to the regulation of GM foods—ranging from pre-
market approval requirements, bans, and strict monitoring to voluntary guidelines for 
the industry—originate from differences in the attitudes towards GM foods between 
the United States and the international community.12 In the international community, 
heated debates have focused on the public health, safety, and environmental issues 
of introduced genes, particularly, allergenicity, antibiotic resistance, gastrointestinal 
problems, potential gene fl ow to other organisms, and destruction of biodiversity.13 
Most signifi cant is the way U.S. and foreign regulators have reacted to these concerns, 
refl ecting confl icting perceptions and views of the potential risks involved with GMOs 
and how to manage these risks.
As GMOs become an increasingly dominant part of the U.S. food supply, it is impor-
tant to explore the basis for these concerns and the disparity in the regulatory responses 
to this technology. Part II of this article analyzes the science of GMOs, particularly the 
potential risks and level of uncertainty. Part III examines the rigorous regulatory scheme 
set forth by the international community in response to this scientifi c uncertainty. Part IV 
discusses the relatively unrestrictive approach of the United States towards GM foods, 
which contrasts markedly with the view overseas. Part V establishes the foundation for 
a new regulatory approach in the United States, while considering the increased costs, 
based on increased consumer demand and the need for transparency to make choice 
possible. Accordingly, this article sets forth an expanded model for the United States 
7 FDA, List of Completed Consultations on Bioengineered Foods (Nov. 2005), http://www.cfsan.
fda.gov//~lrd/biocon.html; see also Monsanto, Products and Solutions, Setting the Standard in the Field, 
http://www.monsanto.com/monsanto/layout/products/default.asp (last visited May 11, 2006) (bringing to 
market second generation of biotechnological traits, e.g., soybeans that can reduce the amount of trans fat 
in processed foods).
8 Associated Press, Americans Clueless About Gene-Altered Foods (Mar. 24, 2005) [hereinafter 
Americans Clueless], available at http://pewagbiotech.org/newsroom/summaries/display.php3?NewsID=857 
(statement of Stephanie Childs, Grocery Manufacturers of America).
9 Id.; see also Roger N. Beachy, Facing Fear of Biotechnology, 285 SCI. 335 (1999), available at www.
biotech-info.net/facing_fear.html.
10 Americans Clueless, supra note 8.
11 For a discussion of the EU moratorium and the efforts of the United States to challenge the ban in 
the WTO, see infra notes 104-06, 161-63 and accompanying text.
12 Pan, supra note 1, at 232; see also Farid E. Ahmed, Detection of  Genetically Modifi ed Organisms 
in Food, 20 TRENDS BIOTECHNOLOGY 215 (2002).
13 Ahmed, supra note 12, at 215.
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of mandatory labeling and pre- and postmarket monitoring, including the development 
of more sophisticated testing and tracking of GM food components. Part VI concludes 
that, in light of scientifi c uncertainty and risks of unintended adverse effects, a more 
cautious approach akin to the international scheme should be adopted in the United 
States. By fulfi lling its responsibility to respond appropriately to the concerns of its 
citizens, the U.S. government actually would be aiding the viability of GM development 
in the long run—thereby facilitating industry efforts to gain acceptance, building con-
sumer confi dence in the food supply, and opening additional markets to their products. 
More stringent monitoring and labeling of GMOs in the food supply is critical for the 
biotechnology and food industries, as well as consumers, particularly in the area of 
international trade. Only by implementing standards of accountability and regulations 
comparable to the international community can the United States truly achieve its goal 
of opening the global marketplace to U.S. agricultural products.
II. THE SCIENCE: RISKS AND UNCERTAINTY
Any fair examination of biotechnology in agriculture should acknowledge the po-
tential benefi ts of genetically engineered foods. A study commissioned by the World 
Health Organization (WHO) cited several benefi ts of this food technology, including the 
potential for increased agricultural productivity and improved nutritional values, along 
with “reduced agricultural chemical usage and enhanced farm income, and improved 
crop sustainability and food security, particularly in developing countries.”14 Proponents 
point to the goals of reducing hunger by increasing food productivity; conserving the 
environment by reducing pesticide and herbicide use; enhancing nutritional content; 
and improving food quality.15 Many would argue, however, that the opportunity to direct 
biotechnology to meet these lofty goals has been squandered (e.g., on the development 
of herbicide resistant plants engineered to survive the spraying of these pesticides or 
“terminator” seeds that cannot reproduce, forcing these impoverished developing coun-
tries to buy additional seeds from the manufacturer). Moreover, these largely unrealized 
benefi ts in fact may be outweighed by the potential of new dangers to human health 
and the environment.
The WHO study identifi ed several risks presented by GMOs and GM foods for hu-
man health as part of its safety assessment, including: direct health effects (toxicity), 
tendencies to provoke allergic reaction (allergenicity), specifi c components with toxic 
properties, the stability of the inserted gene, nutritional impact, and any unintended ef-
fects that could result from genetic modifi cation.16 Of particular concern is gene transfer, 
whereby genes from bioengineered foods could transfer to bacteria in the gastrointes-
tinal tract or to cells of the body and cause negative health effects.17 For example, if 
the antibiotic-resistant marker genes that typically are inserted with GM material to 
facilitate identifi cation of GM cells were transferred, a person could become resistant 
14 WORLD HEALTH ORGANIZATION (WHO), MODERN FOOD BIOTECHNOLOGY, HUMAN HEALTH AND DEVELOP-
MENT: AN EVIDENCE-BASED STUDY, at iii (June 24, 2005) [hereinafter WHO STUDY], available at http://www.
who.int/foodsafety/publications/biotech/biotech_en.pdf; see also Fred Gould  & Michael B. Cohen, Sustain-
able Use of Genetically Modifi ed Crops in Developing Countries, in AGRICULTURAL BIOTECHNOLOGY AND THE 
POOR: CONFERENCE PAPERS 139 (Oct. 1999), available at http://www.cgiar.org/biotech/rep0100/Gould.pdf 
(discussing the potential of biotechnology crops for increasing yield in developing countries, but recognizing 
the need for long-term food security and decreased environmental risks).
15 Pan, supra note 1, at 230.
16 See WHO STUDY, supra note 14.
17 WHO, Questions on GM Foods, supra note 4.
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to antibiotic medicines. Consequently, WHO cautions against using antibiotic-resistant 
genes in the GM process.18
In addition to human health risks, GM foods pose potential risks for the environment, 
named in the WHO study as: “unintended effects on non-target organisms, ecosystems, 
and biodiversity.”19 The Bt bacterium used to produce insect-resistant GM crops may 
cause harmful effects on benefi cial insects or development of resistant insects.20 Another 
concern is the spread of transgenes in the natural environment; the WHO study reports that 
such outcrossing occurred in “fi elds of commercially grown GM plants, including oilseed 
rape and sugar beet, and has been demonstrated in experimental releases for a number of 
crops, including rice and maize.”21 Ultimately, there is a fear that through cross-pollination 
GMOs may become the dominant species and irreversibly alter the ecosystem.22
Despite these identifi ed risks, GM crops continue to be developed and GM food 
continues to be consumed by a public largely unaware of the potential hazards.23 Few 
long-term scientifi c studies have been completed.24 Arpad Pusztai, a scientist who has 
reviewed the research and advocates additional studies on the human health effects of 
GM food, attributes the lack of data to a number of reasons, including the fact that it is 
“more diffi cult to evaluate the safety of crop-derived foods than individual chemical, 
drug, or food additives. Crop foods are more complex and their composition varies 
according to differences in growth and agronomic conditions.”25 In the few animal 
studies that have been done, some of the initial fi ndings have been troubling, includ-
ing the following results: when fed GM tomatoes, some rats died within a few weeks; 
after eating GM soybeans, rats had inadequate weight gain; rats that had ingested GM 
corn had a decreased digestive ability; toxins were present in mice that had eaten GM 
potatoes; the toxin level of GM cotton was deemed “unpredictable”; and GM soybeans 
contained increased allergens.26 These studies have prompted some scientists to recom-
mend “more and better testing methods before making GM foods available for human 
consumption.”27
18 Id. (FAO/WHO expert panel recommendations). At least one study found that the antibiotic-resistant 
marker from a burger containing GM soy found its way into human gut bacteria; “the bacteria had taken 
up the herbicide-resistant gene from the GM food at a very low level.” Study Shows Disadvantages of GM 
Foods to Human Health, GUARDIAN, Aug. 2002, available at http://www.non-gmosource.com/disadvantages_
GM_food_health.php; see also THE ROYAL SOCIETY, GENETICALLY MODIFIED PLANTS FOR FOOD USE AND HUMAN 
HEALTH—AN UPDATE (Feb. 2002), available at http://www.royalsoc.co.uk/displaypagedoc.asp?id=11319.
19 WHO STUDY, supra note 14.
20 Id.
21 Id.
22 See, e.g., Pan, supra note 1, at 231; Nathan Batalion, 50 Harmful Effects of Genetically Modifi ed 
Food (2000), http://www.cqs.com/50harm.htm.
23 Arpad Pusztai, Genetically Modifi ed Foods: Are They a Risk to Human/Animal Health? (June 2001), 
http://www.actionbioscience.org/biotech/pusztai.html (noting that safety test technology is inadequate to 
assess potential harm, that GM foods can carry unpredictable toxins, and that GMOs may increase the risk 
of allergenic reactions).
24 DONNA U. VOGT & MICKEY PARISH, FOOD BIOTECHNOLOGY IN THE UNITED STATES: SCIENCE, REGULATION, 
AND ISSUES (CRS Rep. RL30198) (Jan. 19, 2001) [hereinafter CRS REPORT], available at http://ncseonline.
org/NLE/CRSreports/science/st-41.pdf.
25 Id. (citing Jose L. Domingo, Health Risks of Genetically Modifi ed Foods: Many Opinions But Few 
Data, 288 SCI. 1748 (2000)).
26 Pusztai, supra note 23; see also Batalion, supra note 22. But see ROYAL SOCIETY UPDATE, supra note 
18 (“studies, on the results of feeding GM sweet peppers and GM tomatoes to rats, and GM soya to mice 
and rats, have [found] no adverse effects”) (citing Michael Gasson & Derek Burke, Scientifi c Perspectives on 
Regulating the Safety of Genetically Modifi ed Foods, 2 NATURE REVIEWS GENETICS 207, 217 (2001)).
27 Pusztai, supra note 23. For a related examination of the health issues, see, for example, MARIE-CLAIRE 
CORDONIER SEGGER & ASHFAQ KHALFAN, SUSTAINABLE DEVELOPMENT LAW: PRINCIPLES, PRACTICES, AND PROSPECTS 
(Oxford Univ. Press 2004); see also Craig Segall, Book Review, 24 STAN. ENVTL. L.J. 341 (2005) (reviewing 
MARIE-CLAIRE CORDONIER SEGGER & ASHFAQ KHALFAN, SUSTAINABLE DEVELOPMENT LAW: PRINCIPLES, PRACTICES, 
continued
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Some of the potential hazards of bioengineered foods already have been revealed in 
several cases. One of the fi rst GM products brought to market—a genetically altered 
version of the dietary supplement L-tryptophan—illustrated the risks of toxicity to 
humans. When Showa Denko, Japan’s third largest chemical company, introduced the 
GM version of L-tryptophan into the United States in the late 1980s, at least 1500 people 
were permanently disabled and thirty-seven died from neurological problems connected 
with eosinophilia-myalgia syndrome. It took months before the doctors who treated the 
syndrome noticed the link to patients taking tryptophan produced by Showa Denko, 
which contained a toxic contaminant determined to be a byproduct of the increased 
tryptophan production of the genetically engineered bacteria.28 If the supplement had 
been labeled as genetically engineered, the source of the problem might have been 
discovered sooner and the product removed from the market more promptly.29
Allergies also are a signifi cant concern with GM food, especially if these ingredients 
are not labeled, but “there are no reliable ways to test GM foods for allergies.”30 When 
Pioneer Hi-Bred spliced Brazil nut genes into a soybean to improve its protein content, 
the altered soybean provoked severe allergic attacks in eight individuals sensitive to 
Brazil nuts but not soybeans.31 Fortunately, due to unique circumstances, including 
awareness that this type of nut could be a serious allergen and serum samples from 
persons allergic to the donor species were available for testing, the testing was done 
premarket and the company withdrew the product.32 This case illustrates the dangers of 
the absence of labeling; without a label alerting consumers that a soybean could contain 
genes from a highly allergic nut, even individuals aware of their severe allergies would 
have no warning.33
There have been suggestions that certain ingredients in GM foods may even be linked 
to cancer.34 In 1994, the Food and Drug Administration (FDA) approved Monsanto’s 
recombinant Bovine Growth Hormone (rBGH), also known as, bovine somatotropin 
AND PROSPECTS (Oxford Univ. Press 2004)); Heather N. Ellison, Genetically Modifi ed Organisms: Does the 
Current Regulatory System Compromise Consumer Health?, 10 PENN ST. ENVTL. L. REV. 345 (2002); Julie 
Teel, Rapporteur’s Summary of the Deliberative Forum: Have NGO’s Distorted or Illuminated the Benefi ts 
and Hazards of Genetically Modifi ed Organisms?, 13 COLO. J. INT’L ENVTL. L. & POL’Y 137 (2002); Ellen 
Messer, Food Systems and Dietary Perspective: Are Genetically Modifi ed Organisms the Best Way to Ensure 
Nutritionally Adequate Food?, 9 IND. J. GLOBAL LEGAL STUD. 65, 69-70 (2001).
28 Arthur N. Mayeno & Gerald J. Gleich, Eosinophilia Myalgia Syndrome and Tryptophan Production: 
A Cautionary Tale, 12 TRENDS BIOTECHNOLOGY 346 (1994).
29 Batalion, supra note 22 (citing Arthur N. Mayeno & Gerald J. Gleich, Eosinophilia Myalgia Syndrome 
and Tryptophan Production: A Cautionary Tale, 12 TRENDS BIOTECHNOLOGY. 346 (1994)); see also Jean Hal-
loran & Michael Hansen, Why We Need Labeling of Genetically Engineered Food, 18 SYNTHESIS/REGENERATION 
(1999), available at http://www.consumersunion.org/food/whywenny798.htm (detailing potential allergic, 
toxic, and antibiotic resistance effects of genetically altered food).
30 Pusztai, supra note 23.
31 Julie A. Nordlee et al., Identifi cation of a Brazil Nut Allergen in Transgenic Soybeans, 334 NEW 
ENG. J. MED. 688 (1996). 
32 Marion Nestle, Allergies to Transgenic Foods: Questions of Policy, 334 NEW ENG. J. MED. 726 
(1996).
33 “About 25% of Americans have adverse reactions to foods. 8% of children and 2% of adults have 
food allergies as tested by blood immunoglobins.” Some “individuals … are so allergic to [the Brazil] nut, 
they go into apoplectic shock (similar to a severe bee sting reaction), which can cause death.” Batalion, supra 
note 22. Because the typical focus is on “food with genes transferred from the 8 to 10 most commonly al-
lergenic foods, public-interest groups have cautioned that existing rules inadequately protect people against 
lesser-known transgenic allergens to which they might be sensitive.” Nestle, supra note 32.
34 Several GM food products approved for use in the United States “involve herbicides that are com-
monly known carcinogens—bromoxynil used on transgenic cotton and Monsanto’s Roundup or glufonsinate 
used on GM soybeans, corn, and canola.” In addition, “unexpected gene fragments have shown up in GM 
soy crops”—and research has shown that “foreign DNA fragments that are not fully digested in the human 
stomach and intestines” enhance a number of autoimmune diseases. Batalion, supra note 22.
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(BST), a genetically produced growth hormone, for injection into dairy cows, disre-
garding warnings from scientists of the resulting increase of IGF-1, a potent chemical 
hormone with evidence indicating 400% to 500% higher risks of human breast, prostrate, 
and colon cancer.35 Studies show that rBGH increases the levels in milk of insulin-like 
growth factor (IGF-1), a powerful stimulator and regulator of cell-growth and division 
in cows and humans—particularly children—that has been linked to cancer.36 Despite 
these concerns, FDA has repeatedly defended its approval of rBGH, publishing a 
review of the data and concluding that rBGH “presents no increased health risk.”37 In 
May 1994, FDA’s Food Advisory Committee and Veterinary Medicine Advisory Com-
mittee discussed whether foods should be labeled as containing supplemental rBGH; 
the committee report stated that “deliberations indicate that any method for instituting 
labeling for food from BST-supplemented cows would have to resolve many diffi cult 
scientifi c and policy questions.”38 To date, no such labeling of milk products is required 
by FDA.39 Furthermore, the courts have deferred to the agency position on the nonla-
beling of rBGH.40
The potential impact of GMOs on ecosystems was dramatically exhibited by a study 
of biotech corn and monarch butterfl ies at Cornell University.41 When scientists applied 
pollen from Bt-corn to milkweed, a crop that the butterfl ies eat and that grows near corn-
fi elds, forty-four percent of the monarch larvae died.42 None of the monarch larvae in the 
study that were fed corn pollen from nonengineered plants died.43 Some scientists caution 
that additional research needs to be done, for example, in the monarch butterfl y’s natural 
habitat, before concluding that widespread harm to the ecosystem will result.44 Still, the 
35 Id.
36 Press Release, Cancer Prevention Coalition, New Study Warns of Breast and Colon Cancer Risks from 
rBGH Milk (Jan. 23, 1996), available at http://www.preventcancer.com/press/conference/jan23_96.htm; see 
also, Samuel Epstein, Potential Public Health Hazards of Biosynthetic Milk Hormones, 20 INT’L J. HEALTH 
SERVS. 73 (1990); National Institutes of Health, Technology Assessment Conference Statement on Bovine 
Somatotropin, 265 JAMA 1423 (1991).
37 CRS REPORT, supra note 24. On December 15, 1998, the nonprofi t organization Center for Food 
Safety petitioned FDA to withdraw approval of rBGH due to possible health effects not addressed by the 
agency. As of January 2001, this issue was pending within FDA. Critics continue to question the data upon 
which FDA founded its reports and the agency’s close ties with Monsanto. See, e.g., David I. Aboulafi a, 
Pushing rBST: How the Law and the Political Process Were Used to Sell Recombinant Bovine Somatotropin 
to America, 15 PACE ENVTL. L. REV. 603 (1998).
38 Id.
39 Id. Moreover, FDA rejected the request by some companies to label their milk products as “BST-free,” 
determining that because BST (BGH) is a normal constituent of milk, such labeling would be misleading.
40 In Stauber v. Shalala, 895 F. Supp. 1178, 1193 (W.D. Wis. 1995), the court deferred to FDA’s fi nding 
that there was no difference between dairy products from rBGH or nontreated cows. Thus, the court upheld 
FDA’s determination that it would not require labeling disclosing that dairy products came from rBGH-treated 
cows. When the state of Vermont sought to require mandatory disclosure of rBGH use in milk production, 
the U.S. Court of Appeals for the Second Circuit struck down the Vermont law on grounds that “consumer 
curiosity” was not “substantial” enough to justify the intrusion on commercial free speech under the First 
Amendment. Int’l Dairy Foods Ass’n v. Amestoy, 92 F.3d 67, 74 (2d Cir. 1996). See Emily Marden, Recom-
binant Bovine Growth Hormone and the Courts: In Search of Justice, 46 DRAKE L. REV. 617 (1998).
41 Arjun Makhijani, Ecology & Genetics: An Essay on the Nature of Life and the Problem of Genetic 
Engineering, ch. 5 (Apex Press 2001). See John E. Losey, Linda S. Rayor & Maureen E. Carter, Transgenic 
Pollen Harms Monarch Larvae, 399 NATURE 214 (1999), available at http://www.biotech-info.net/transpol-
len.html.
42 Id.
43 Id.; see also Danielle Knight, Environment: New Report Fuels Debate on GMO’s, ENVTL. BULL., 
June 4, 2001, at 1, 2.
44 For example, researchers point out that most milkweed on which monarch larvae feed does not grow 
close enough to cornfi elds to be exposed to signifi cant amounts of corn pollen. Further, the timing is important 
and the monarch larvae would have to be emerging and feeding at the same time the corn is pollinating; they 
would have other food choices as well. Additional research is underway to determine whether Bt-corn poses 
continued
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fact that ingesting Bt-corn had this effect is troubling. A report from the nongovernmen-
tal Institute for Energy and Environmental Research (IEER) concluded from this study, 
“Whether Bt corn will actually have severe impacts on monarch butterfl y populations is 
less important to the overall issue than the fact of the unanticipated toxicity of Bt corn 
pollen. It should serve as a huge warning signal of the possibility of ecosystem disruption 
due to the widespread introduction of engineered species.”45
Outcrossing also could have a direct impact on human health and food safety, as 
was demonstrated when traces of a maize type that was only approved for feed use 
appeared in maize products for human consumption in the United States.46 StarLink, 
a corn genetically engineered with a [Cry9C] protein to protect crops against certain 
insects, was considered suitable only for animal feed because of concerns that it could 
cause allergic reactions in humans; but StarLink accidentally entered the food supply, 
prompting a large scale recall of about 300 corn products.47 In addition, the cross-con-
tamination had an impact on international trade, causing a drop in Japanese imports 
of U.S. corn by 1.3 million metric tons (eight percent in volume terms) in 2001. The 
Japanese government now mandates the segregation of unapproved biotechnology food 
and feed ingredients from the export channel, allowing a one percent tolerance for the 
unintended presence of these components.48
Further concerns about the U.S. food supply come from the latest use of biotech-
nology in crops to generate the production of drugs. A small biotechnology company, 
Ventria Biosciences, plans to insert human genes into rice plants to produce two pro-
teins normally found in breast milk, tears, and saliva, in turn generating “therapeutic 
food products to treat stomach disorders.”49 Several other biotechnology companies are 
experimenting with drugs grown in plants because using this GM method to produce 
drugs in mass quantities of fi eld plantings is less costly than a traditional biotechnology 
factory.50 A consulting fi rm forecasts that the fi rst plant-manufactured drugs will reach 
the U.S. market next year and expand into a $2.2 billion-per-year industry by 2011.51
Consumer and environmental advocates, and many farmers (i.e., American Farm 
Bureau and National Farmers Union), fear that pollen from GM drug plants could drift 
into fi elds containing food crops and create contaminated hybrids.52 Moreover, a bird 
could ingest the bioengineered seeds and deposit them in a fi eld hundreds of miles 
a signifi cant danger to the monarch butterfl y in the long run. See Novartis, Q & A: Monarch Butterfl ies and 
Bt Corn, Syngenta Cuts (2000), http://www.checkbiotech.org/blocks/dsp_document.cfm?doc_id=83; U.S. 
Dep’t of State, Fact Sheet: Monarch Butterfl ies and Bt Corn: A Review of the Research, 4 ECON. PERSP. (1999), 
http://usinfo.state.gov/journals/ites/1099/ijee/bio-monarch.htm.
45 Press Release, Inst. for Energy and Envtl. Research (IEER), Ecological Impacts of Genetically Engi-
neered Plants May Be Severe Harm Possibly Greater Than From Toxic Chemicals (June 4, 2001), available 
at http://www.ieer.org/comments/genetics/e&g-prl.html (statement of Arjun Makhijani, President, IEER).
46 WHO, Questions on GM Foods, supra note 4, at Q5.
47 Martin A. Lee, Food Fight: International Protests Mount Against Genetically Engineered Crops, S.F. 
BAY GUARDIAN, June 25, 2001, available at http://www.gefoodalert.org/News/news.cfm?News-ID=w2780 
(“While acknowledging that nearly a half billion bushels of corn in storage nationwide contain StarLink, 
Aventis denies that it poses a health risk to humans.”).
48 James Stamps, Trade in Biotechnology Food Products, INT’L ECON. REV. 5, 13-14 (2002); see also 
StarLink Information Center, StarLink History, StarLink—What Happened?, http://www.starlinkcorn.com/
History/What%20Happened.htm (last visited May 11, 2006).
49 Arlene Weintraub, What’s So Scary About Rice? Biotech Crops Can Make Drugs—But They Must 
Be Kept Out of the Food Chain, BUS. WK., Aug. 1, 2005, at 58.
50 “A traditional biotech factory might cost Ventria … $125 million,” but rice yields “the same output 
for $4 million.” Chief Executive Offi cer Scott Deeter says “he intends to pass the savings to consumers. Id.
51 Id.
52 Id.
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away.53 Even others in industry resist the use of biotech crops for drug production; 
Anheuser-Busch has waged a battle against this development in Missouri, fearing con-
tamination of the rice plants that are a key ingredient in the company’s beer.54 Margaret 
Mellon, Director of the Food and Environment program for the Union of Concerned 
Scientists in Washington, D.C. warns that it is “virtually certain this stuff will make it 
into food-grade rice.”55
Along with risks to the consumer and the environment come signifi cant potential con-
sequences for international trade. Some $1.3 billion in annual U.S. rice sales to foreign 
countries are at stake.56 If drugs migrate into commodity crops, many of these countries, 
already wary of biotech crops, would buy their agricultural products elsewhere.57 These 
fears are not unfounded, as revealed by an incident in 2002, when a drug-producing 
corn made by ProdiGene Inc. began sprouting in soybean fi elds near its Nebraska and 
Iowa sites.58 The U.S. Department of Agriculture (USDA) seized 500,000 bushels of 
contaminated soybeans and charged ProdiGene nearly $3 million in fi nes and disposal 
costs. Unless companies and the agencies that regulate them implement safeguards to 
prevent these food-safety fears from becoming a reality, this biotech method of drug 
production faces an unsteady future.59
The favored method of the U.S. industry has been to make comparisons between 
the compositions of GM and non-GM crops. When they are not signifi cantly different 
the two are regarded as “substantially equivalent,” and, therefore, the GM food crop 
is regarded as safe as its conventional counterpart. As discussed infra, FDA relies on 
this substantial equivalence for its view that no additional labeling or animal testing is 
required. Substantial equivalence is an unscientifi c concept, however, that has never 
been properly defi ned or provided with a legal standard for implementation.60 The IEER 
report states that:
Tests have not been performed because the regulatory apparatus has bought 
into the scientifi cally unfounded doctrine of “substantial equivalence,” ac-
cording to which there are assumed to be no differences between genetically 
engineered and traditionally bred foods. Today we want to emphasize that this 
erroneous notion of “substantial equivalence” at the level of food composition 
has its analog at the level of ecological impacts.61
53 Id.
54 Id. In April 2004, when Anheuser-Busch threatened to boycott all Missouri rice, Ventria shifted its 
plans; in June 2005, USDA approved Ventria’s application for plants in North Carolina instead.
55 Id. In an interview, Margaret Mellon of the Union of Concerned Scientists further explained, “when 
you’re genetically engineering bioactive molecules—drugs—into crops and they’re growing outdoors, you 
must be able to assure those [engineered traits] don’t move to food crops. Otherwise you’re imposing health 
and environmental risks.” Online Extra: The Side Effects of Drugged Crops, BUS. WK., July 26, 2005, http://
www.businessweek.com/magazine/content/05_31/b3945092mz018.htm.
56 Weintraub, supra note 49. 
57 Id.; Online Extra, supra note 55. 
58 Weintraub, supra note 49, at 58; see also Spotlight Pharming Reaps Regulatory Changes, AGBIO-
TECH BUZZ, May 14, 2003, http://pewagbiotech.org/buzz/display.php3?StoryID=101(seeds inadvertently left 
behind in former test sites mingled with soybeans that were harvested and stored before the situation was 
discovered). Two months earlier, Prodigene had to destroy 155 acres of corn in Iowa because wind-blown 
pollen from its drug-producing may have contaminated that too. Take Action, http://www.seedsofdeception.
com/Public/TakeAction/index.cfm (last visited May 17, 2006).
59 Weintraub, supra note 49, at 58-59; see also Carie-Megan Flood, Note, Pollen Drift and Potential 
Causes of Action, 28 J. CORP. L. 473, 477-82 (2003) (for legal liability issues associated with these envi-
ronmental risks).
60 Pusztai, supra note 23 (citing Erik Millstone et al., Beyond Substantial Equivalence, NATURE, OCT. 
7, 1999, AT 525).
61 IEER Press Release, supra note 45 (statement of Martha R. Herbert, M.D., Ph.D., Pediatric Neurolo-
gist, Harvard Medical School).
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It is for this reason that this approach has been rejected in Europe, where the capability 
to classify a novel food as being substantially equivalent no longer justifi es a lack of 
safety assessments.62
According to some of the major regulatory and scientifi c agencies in the world, GM 
crops possess greater dangers than traditional crop breeding methods.63 Scientists have 
identifi ed the following as key issues in the environmental assessment of GM crops: 
putative invasiveness; vertical or horizontal gene fl ow; other ecological impacts; effects 
on biodiversity; and the impact of the presence of GM material in other products.64 In 
view of the complexities of these issues, skilled ecologists and other scientists with 
expertise in developing the necessary predictive tools for risk assessment must have a 
voice in the public debate.65
A National Academies of Sciences (NAS) National Research Council report clarifi es 
that “[t]he process of genetic engineering has not been shown to be inherently dangerous, 
but rather, evidence to date shows that any technique, including genetic engineering, 
carries the potential to result in unintended changes in the composition of the food.”66 
Distinguishing between genetic engineering methods67 and nongenetic engineering 
methods68 of modifying plants and animals, the report has suggested some possible 
mechanisms of unintended change for organisms genetically engineered using rDNA 
techniques. For example, chromosomal changes may occur depending on where the 
genes were inserted, there may be a loss or gain of whatever function the gene provided, 
and spontaneous mutation may occur. As a result, the committee concluded that genetic 
engineering presented the greatest likelihood of unintended health effects on its scale in 
comparison to nongenetic engineering methods. The National Research Council report 
observed that targeted, quantitative analysis—the traditional approach of determining 
the presence or amount of compounds produced to assess changes and potential harm to 
health—has become much more sophisticated in detecting small molecules, but “more 
improvements are still needed.”69
62 See ROYAL SOCIETY UPDATE, supra note 18.
63 NATIONAL RESEARCH COUNCIL, GENETICALLY MODIFIED PEST-PROTECTED PLANTS: SCIENCE AND REGULATION 
(Nat’l Acad. Press 2000); Declan Butler & Tony Reichhardt, Long-Term Effect of GM Crops Serves Up Food 
for Thought, NATURE, Apr. 22, 1999, at 651-56; see also John E. Beringer, Releasing Genetically Modifi ed 
Organisms: Will Any Harm Outweigh Any Advantage?, 37 J. APPLIED ECOLOGY 207 (2000) (arguing that most 
concerns about environmental harm are more relevant to existing crops, that virtually all changes in agricultural 
practice have an adverse impact on wildlife, and identifying the problem as how to manage agriculture to 
ensure that we maintain or enhance species diversity of wild plants and animals within this context).
64 Anthony J. Conner et al., The Release of Genetically Modifi ed Crops Into the Environment, 33 
PLANT J. 19 (2003); see also Stephen Tromans, Promise, Peril, Precaution: The Environmental Regulation 
of Genetically Modifi ed Organisms, 9 IND. J. GLOBAL LEGAL STUD. 187 (2001).
65 Alan J. Gray, Ecology and Government Policies: The GM Crop Debate, 41 J. APPLIED ECOLOGY 1 
(2004). See generally Margaret Rosso Grossman, Biotechnology, Property Rights and the Environment, 50 
AM. J. COMP. L. 215, 217-23 (Supp. 2002) (outlining the risks and benefi ts associated with GM foods).
66 NRC SAFETY, supra note 3, at 1.
67 Two GE methods (targeted) were described: microbial vectors, a method that takes advantage of a 
microbe’s ability to transfer and stably integrate segments of DNA into a plant so that the plant expresses 
those traits, and electroporation. In the latter process, plant cells growing in culture are stripped of their 
protective walls and electric shock is used to destabilize the cell membrane and allow the introduced DNA 
to enter the cell. Id.
68 Non-GE methods (nontargeted) include: simple selection, in which plants with desired traits are 
selected for continuous propagation; crossing, brushing pollen from one plant onto a sexually compatible 
plant to produce a hybrid with genes from both parents; embryo rescue, placing a plant that has naturally 
cross-pollinated into a tissue culture environment to enable its full development; and mutagen breeding, 
exposing plants or seeds to mutagenic agents (e.g., ionizing radiation) or chemicals to induce random change 
in the DNA sequence and assess the new plants for valuable traits. Id.
69 Id. at 2.
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The National Research Council report proposed a new framework that could be 
used to examine, identify, and evaluate systematically the unintended compositional 
changes and health affects of all altered foods, including a safety assessment prior to 
commercialization and postmarket surveillance to monitor unanticipated compositional 
changes and health effects of genetically engineered foods.70 Most signifi cantly, the 
report called for additional research such as developing new tools for detecting health 
changes in the population that could result from genetic alteration and for assessing 
potential unintended adverse effects.71
III. A CAUTIOUS APPROACH: EUROPEAN UNION 
AND INTERNATIONAL LAW
In the face of such signifi cant concerns in the scientifi c community as to the safety 
of GMOs in food, how do regulatory systems proceed? Viewing this level of risk to 
be unacceptable, Europeans and the international community take a more cautious ap-
proach than the United States. In seeking an explanation for the greater opposition to 
food biotechnology in Europe, a study found that different histories of media coverage 
and regulation combined with public perceptions that refl ected deeper cultural sensi-
tivity not only toward food and novel food technologies but also toward agriculture 
and the environment.72 Until recently, consumers in the United States have appeared 
to be relatively trusting and uninformed of a technology that in Europe has triggered 
extensive public debate, due in part to a history of food and environmental concerns, 
lack of transparency, and suspicion towards the government.73
The divergent legal approaches refl ect this cultural difference in attitudes through the 
level to which scientifi c uncertainty is factored into risk assessment as part of the regula-
tory process. The international community gives greater weight to this uncertainty than 
does the U.S. government in its treatment of GMOs.74 Because U.S. regulators do not view 
biotechnology as posing special risks in and of itself, the regulatory treatment of biotech 
products has been limited to fi tting them within existing laws addressing known physical 
risks of new products.75 In contrast, European regulators have dealt with biotechnology 
as “a novel process requiring novel regulatory provisions,” and, as a consequence, have 
launched a complex series of European and international initiatives that take into account a 
wider range of both known and unknown risks to human health and the environment.76
To provide international consistency in the assessment of GM foods, the Codex Ali-
mentarius Commission—an international standard setting body for food safety jointly 
administered by two United Nations agencies, the Food Agriculture Organization (FAO) 
and WHO—adopted principles that set a uniform standard for assessing food safety for 
foods derived from modern biotechnology.77 The Codex principles set forth a premarket 
70 Id.
71 Id. at 3; see also infra note 212 and accompanying text.
72 George Gaskell et al., Worlds Apart? The Reception of Genetically Modifi ed Foods in Europe and 
the U.S., 285 SCI. 384 (1999) (an attitudinal study analyzing public perceptions of biotechnology, together 
with press coverage and policy formation).
73 Id.; Ahmed, supra note 12, at 215; see also Alexander G. Haslberger, Monitoring and Labeling for 
Genetically Modifi ed Products, 287 SCI. 431 (2000).
74 Haslberger, supra note 73.
75 Gaskell et al., supra note 72.
76 Id.
77 Codex Alimentarius Commission, Principles for the Risk Analysis of Food Derived from Modern 
Biotechnology, CAC/GL 44-2003 (2003), available at http://www.codexalimentarius.net/download/stan-
dards/10007/CXG_044e.pdf.
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assessment, implemented on a case-by-case basis, including an evaluation of both direct 
effects from the inserted gene and unintended effects that may arise as a consequence 
of insertion of the new gene. The safety assessment principles for GM foods require an 
investigation of the risks previously identifi ed, namely, toxicity, allergenicity, specifi c 
components having nutritional or toxic properties, the stability of the inserted gene, the 
nutritional effects of the specifi c gene modifi cation, and any unintended effects from 
the gene insertion.78 Treaties such as the Agreement on the Application of Sanitary and 
Phytosanitary Measures of the World Trade Organization (WTO) embrace the Codex 
principles, even though the Codex does not in itself have a binding effect on national 
legislation. These principles are further referred to as a standard in cases of trade dis-
putes, including those involving the United States.79
In evaluating this approach to biotechnology and food safety, WHO in its recent 
study concluded that the risk assessment guidelines specifi ed by the Codex Commis-
sion are “thought to be adequate for the safety assessment of GM foods currently on 
the international market.”80 The study determined that GMOs and GM foods should be 
assessed on a case-by-case basis for potential risks, while taking into account their char-
acteristics and possible differences in the receiving environments. In particular, relevant 
consequences must be investigated for specifi c crops and strategies for risk management 
explored to detect potential risks from outcrossing or contamination from GM crops. 
A better understanding of the impact and interaction of food with the immune system 
also is required to ascertain how and whether conventional and GM foods cause specifi c 
health and safety problems. WHO supported the Codex Commission in its expectation 
that improvements in risk assessment techniques will be included in the premarket ap-
proval process launched by many countries under this international guidance.81
As the only international regulatory instrument established to protect biological 
diversity from the risks of biotechnology, the Cartagena Protocol on Biosafety of the 
Convention on Biological Diversity82 expressly focuses on the potential adverse ef-
fects of “living modifi ed organisms” (LMOs) on the environment, while also taking 
into account the risks to human health as a secondary consideration.83 The Cartagena 
Protocol, an environmental treaty legally binding on its parties, regulates the trade and 
transfer of LMOs across borders, including labeling on shipments of GM commodities.84 
Through an Advance Informed Agreement (AIA), an exporter must inform potential 
78 WHO STUDY, supra note 14, at 12.
79 The United States has participated in Codex since it was formed in 1962. Id.; Stamps, supra note 
48, at 5, 7; see also WHO, Questions on GM Foods, supra note 4.
80 WHO STUDY, supra note 14, at 24.
81 Id.
82 Cartagena Protocol on Biosafety to the Convention on Biological Diversity (2000), available at 
http://www.biodiv.org/biosafety/. The Cartagena Protocol (sometimes referred to as the Biosafety Protocol) 
was put forth in January 2000 and went into effect on September 11, 2003, the ninetieth day after receiving 
the fi fty instruments of ratifi cation by States or regional economic integration organizations that are Parties 
to the UN Convention on Biological Diversity (CBD), which was adopted in Rio de Janeiro in 1992. See 
IISD Linkages, A Brief Introduction to the Convention on Biological Diversity, http://www.iisd.ca/biodiv/
cbdintro.html (last updated Feb. 18, 2000). As of July 27, 2005, there were 125 Parties who had ratifi ed the 
Protocol. The United States, which had signed the CBD, but had not ratifi ed it, is not among them. For a 
list of the status of the ratifying Parties, see The Convention on Biological Diversity, Parties to the Conven-
tion on Biological Diversity/Cartagena Protocol on Biosafety, http://www.biodiv.org/world/parties.asp (last 
visited May 13, 2006).
83 WHO STUDY, supra note 14, at 19.
84 Aarti Gupta, Governing Trade in Genetically Modifi ed Organisms: The Cartagena Protocol on 
Biosafety, 42 ENV’T 22, 22-23 (2000); see also Lisa A. Tracy, Does a Genetically Modifi ed Rose Still Smell 
as Sweet?—Labeling of Genetically Modifi ed Organisms under the Biosafety Protocol, 6 BUFF. ENVTL. L.J. 
129 (1999).
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participatory countries of all of the information associated with these organisms before 
permitting their import. 85
The Cartagena Protocol incorporates a precautionary approach in keeping with the 
language of the Rio Declaration on Environment and Development, that “[w]here there 
are threats of serious or irreversible damage, lack of full scientifi c certainty shall not 
be used as a reason for postponing cost-effective measures to prevent environmental 
degradation.”86 It provides risk scientifi c detection methods and assessment techniques, 
and allows governments to prohibit the import of GM foods because of safety concerns. 
Refl ected in the Cartagena Protocol’s approach is the recognition that, although the 
risks may be unknown,
[l]ack of scientifi c certainty due to insuffi cient relevant scientifi c information 
and knowledge regarding the extent of the potential adverse effects of a liv-
ing modifi ed organism on the conservation and sustainable use of biological 
diversity in the Party of import, taking also into account risks to human health, 
shall not prevent that Party from taking a decision, as appropriate, with regard 
to the import of that living modifi ed organism intended for direct use as food 
or feed, or for processing, in order to avoid or minimize such potential adverse 
effects.87
Lastly, the Cartagena Protocol establishes a Biosafety Clearing-House “to facilitate the 
exchange of scientifi c, technical, environmental, and legal information, and experience 
with, living modifi ed organisms” and to assist countries in the implementation of the 
Protocol.88
According to the WHO study, the Cartagena Protocol is only the fi rst step in the in-
ternational regulation of bioengineered foods.89 Although the Cartagena Protocol is the 
key basis for international regulation of LMOs, the Protocol’s scope does not consider 
GM foods that do not meet the defi nition of an LMO. 90 GM foods are within the scope 
of the Cartagena Protocol only if they contain LMOs that are capable of transferring or 
replicating genetic material. Moreover, the primary focus on biodiversity limits its con-
sideration of human health issues; consequently, “the Protocol alone … is not suffi cient 
for the international regulation of GM foods.”91 In addition, the WHO study reported the 
possibility of implementing postmarket surveillance in the future, but tools to identify 
and trace GMOs or products derived from GMOs in the environment and food chain 
are needed; detection techniques in a number of countries already facilitate monitor-
ing of GMOs, and attempts to standardize analytical methods for tracing GMOs have 
been initiated.92 Lastly, WHO hopes that “this report could form the basis for a future 
85 Cartagena Protocol, supra note 82; see Aarti Gupta, Advance Informed Agreement: A Shared Basis 
for Governing Trade in Genetically Modifi ed Organisms?, 9 IND. J. GLOBAL LEGAL STUD. 265 (2001).
86 Comisión Nacional de Recursos Fitogenéticos, Frequently Asked Questions About the Cartagena 
Protocol on Biosafety, http://www.conarefi .ucr.ac.cr/Bioseguridad1.htm (last visited May 13, 2006).
87 Cartagena Protocol art. 11, para. 8.
88 See Cartagena Protocol art. 20, para. 1. The Biosafety Clearing House is located at http://bch.biodiv.
org/. For a general discussion of the Cartagena Protocol, see David J. Schnier, Genetically Modifi ed Organ-
isms & the Cartagena Protocol, 12 FORDHAM ENVTL. L.J. 377 (2001).
89 WHO STUDY, supra note 14, at 19-20.
90 Under the Cartagena Protocol, a living modifi ed organism (LMO) is defi ned as “any living organism 
that possesses a novel combination of genetic material obtained through the use of modern biotechnology” 
and living organism means “any biological entity capable of transferring or replicating genetic material, 
including sterile organisms, viruses and viroids.” Cartagena Protocol art. 3(g)-(h).
91 WHO STUDY, supra note 14, at 19-20.
92 Id. at 23 (citing European Network of GMO Laboratories (2002), available at http://engl.jrc.it/).
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initiative towards more systematic, coordinated, multi-organizational and international 
evaluation of certain GM foods.”93
Sharing this initiative, the Organization for Economic Cooperation and Development 
(OECD) established the Internal Coordination Group on Biotechnology in 1993 to aid 
international coordination in the areas of agriculture, technology, and trade. The OECD 
BioTrack provides a clearinghouse of information on biotechnology products and fi eld 
trials, as well as Consensus Documents for the Work on Harmonisation of Regulatory 
Oversight in Biotechnology.94 This OECD effort seeks to promote international har-
monization in the safety assessment and regulation of biotechnology food products, 
including conforming food labeling practices, which otherwise would have a potential 
to impede international trade in food products as nontariff trade barriers.95
With its precautionary approach, the European Union (EU) has taken a relatively proac-
tive role in enacting strict legislation to control the spread of GMOs. Most signifi cantly, the 
EU introduced a new Directive, 2001/18/EC,96 regulating and restricting the distribution 
of GMOs and foods containing GM ingredients. The Directive recognizes that
[l]iving organisms, whether released into the environment in large or small 
amounts for experimental purposes or as commercial products, may repro-
duce in the environment and cross national frontiers thereby affecting other 
Member States. The effects of such releases on the environment may be ir-
reversible.97
As a result, the Directive mandates that “[t]he protection of human health and the en-
vironment requires that due attention be given to controlling risks from the deliberate 
release into the environment of [GMOs].”98 Directive 2001/18/EC provides a notifi cation 
procedure before a GM product is placed on the market, a period of public comment, 
an assessment report, and principles for environmental risk assessment. Following a 
“step-by-step” principle, the scale of release is increased gradually only with proper 
evaluation at each step, providing fi rst that
[n]o GMOs, as or in products, intended for deliberate release are to be consid-
ered for placing on the market without fi rst having been subjected to satisfactory 
fi eld testing at the research and development stage in ecosystems which could 
be affected by their use.99
The Directive also sets forth specifi c provisions for labeling and packaging, including 
a requirement that the words “this product contains genetically modifi ed organisms” 
shall appear either on a label or in an accompanying document.100 For products where 
93 WHO, Questions on GM Foods, supra note 4, at Q20.
94 Organisation for Economic Co-operation and Development (OECD), Consensus Documents for 
the Work on Harmonisation of Regulatory Oversight in Biotechnology, http://www.oecd.org/document/51/
0,2340,en_2649_37437_1889395_1_1_1_37437,00.html (last visited May 13, 2006).
95 Stamps, supra note 48, at 8 (citing OECD, Biosafety—BioTrack, About, http://www.oecd.org/
about/0,2337,en_2649_34385_1_1_1_1_37437,00.html (last visited May 13, 2006)).
96 Council Directive 2001/18/EC, 2001 O.J. (L106), available at http://binas.unido.org/binas/regs.php; 
see also Facts on GMOs in the EU, supra note 3.
97 Council Directive 2001/18/EC, supra note 96, at cl. 4.
98 Council Directive 2001/18/EC, supra note 96, at cl. 5.
99 Id. at cls. 24 and 25.
100 Id. at art. 13, § 2, ¶ f. The Directive further calls for a legislative proposal for implementing the 
Cartagena Protocol on Biosafety, including appropriate measures to require community exporters to ensure 
that all requirements of the AIA procedure of the Cartagena Protocol are fulfi lled.
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unavoidable traces of authorized GMOS cannot be excluded, minimum threshold lev-
els for the labeling requirement shall be established.101 Postmarket monitoring by the 
industry is required, as well as notifying the authorities of new information and taking 
immediate measures necessary to protect human health and the environment.102
Extending beyond the previous Directive 90/220/EC,103 the new Directive allows a 
temporary ban of GM products if evidence can be provided exposing risks to human 
health or the environment.104 The moratorium has been a source of friction between 
the United States and the EU, costing the United States an estimated $200 million in 
corn exports.105 The United States has fi led a complaint with the WTO challenging the 
ban, on the grounds that it is an impediment to trade.106 The ban followed an earlier 
action when, in November 2002, the EU approved enhanced traceability and labeling 
requirements for biotechnology food and feed.107 The U.S. government previously had 
delivered a demarche to the EU in September 2002 outlining U.S. concerns about the 
then-pending (traceability and labeling) regulations and their likely adverse impact on 
U.S. bulk shipments.108
In response to a series of food safety alarms, the EU, in May 2003, created the 
European Food Safety Authority (EFSA) to serve as a “food safety watchdog.”109 The 
role of the EFSA differs from its U.S. counterpart in that the EFSA deals only with 
101 Id. at art. 21, § 2.
102 Id. at art. 19, § 2 ¶ f and art. 20.
103 Council Directive 90/220/EEC, 1990 O.J. (L117), available at http://binas.unido.org/binas/regs.
php. Directive 90/220/EEC regulated deliberate releases for research and development and the placing on 
the market of GMOs and products containing a GMO such as GM tomatoes, but did not extend to products 
derived from GMOs, such as paste or ketchup from a GM tomato. It was strengthened through the mandatory 
labeling requirements of Council Regulation (EC) No. 1139/98, 1998 O.J. (L159), available at http://www.
biosafety.be/GB/Dir.Eur.GB/FF/1139_98/1139_98.html. Council Directive 90/220/EEC was repealed by 
the new Directive 2001/18/EC.
104 See generally Brian Schwartz, Note, WTO and GMOS: Analyzing the European Community’s Recent 
Regulations Covering the Labeling of Genetically Modifi ed Organisms, 25 MICH. J. INT’L L. 771 (2004).
105 The Non-GMO Report, EU tightens GM food labeling requirements (Nov. 2002), http://www.non-
gmosource.com/GM_food_labeling_requirements.php; see generally David Winickoff et al., Adjudicating the 
GM Food Wars: Science, Risk, and Democracy in World Trade Law, 30 YALE J. INT’L L. 81 (2005); THOMAS 
BERNAUER, GENES, TRADE, AND REGULATION: THE SEEDS OF CONFLICT IN FOOD BIOTECHNOLOGY (Princeton Univ. 
Press 2003); see Charles R. McManis, Wither the Confl ict over Agricultural Biotechnology?, 6 MINN. J.L. 
SCI. & TECH. 737 (2005) (reviewing THOMAS BERNAUER, GENES, TRADE, AND REGULATION: SEEDS OF CONFLICT 
IN FOOD BIOTECHNOLOGY (2003)).
106 In May 2003, the United States, Argentina, and Canada fi led a formal complaint with the World 
Trade Organization (WTO) against the European Union over its illegal fi ve-year moratorium on approving 
crops improved through biotechnology. Biotechnology Industry Organization, European Union Moratorium, 
http://www.bio.org/foodag/background/eumoratorium.asp (last visited May 13, 2006). But see Press Release, 
European Union, European Commission Regrets U.S. Decision to File WTO Case on GMOs as Misguided 
and Unnecessary (May 23, 2003), available at http://www.eurunion.org/news/press/2003/2003036.htm; see 
also John Stephen Fredland, Unlabel Their Frankenstein Foods!: Evaluating a U.S. Challenge to the European 
Commission’s Labeling Requirements for Food Products Containing Genetically Modifi ed Organisms, 33 
VAND. J. TRANSNAT’L L. 183, 187 (2000).
107 Stamps, supra note 48, at 10.
108 Id. (citing U.S. Demarche Highlights Priority Changes to EU Biotech Rules, INSIDE U.S. TRADE 
(Oct. 11, 2002)). For further analysis on the U.S.-EU debate, see Mystery Bridgers, Comments and Notes, 
Genetically Modifi ed Organisms and the Precautionary Principle: How the GMO Dispute Before the World 
Trade Organization Could Decide the Fate of International GMO Regulation, 22 TEMP. ENVTL. L. & TECH. 
J. 171 (2004); Starla L. Borg, Note, Waiting for the River: The United States and European Union, Heads 
Up and High Stakes in the WTO—Genetically Modifi ed Organisms in International Trade, 43 WASHBURN 
L.J. 681 (2004); Sarah Lively, Comment, The ABCs and NTBs of GMOs: The Great European Union-United 
States Trade Debate—Do European Restrictions on the Trade of Genetically Modifi ed Organisms Violate 
International Trade Law?, 23 NW. J. INT’L L. & BUS. 239 (2002).
109 Geoffrey Podger, European Food Safety Authority Will Focus on Science, 5 EUR. AFF. (2004), avail-
able at http://www.europeanaffairs.org/current_issue/2004_winter/2004_winter_77.php4.
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the science of risk assessment (determining what risks exist), while FDA also handles 
the policy decisions involved in risk management (determining what to do about those 
risks and whether they are considered acceptable). The European Parliament wanted an 
organization that gave “genuinely objective, independent and public advice,” leaving 
the policy judgments to the European Commission.110 Thus, the EFSA will not have a 
role in trade disputes before the WTO, but instead hopes to “help bring American and 
European scientists together at an early stage in the hope of reducing the political impact 
of such differences” because “food safety does not respect boundaries.”111 Another goal 
is to instill “a much clearer degree of scientifi c input into the risk management measures 
adopted by the EU” by taking care not to avoid diffi cult scientifi c issues of risk assess-
ment for fear of unpopularity.112 At the same time, in light of the European sensitivity 
to food issues and past food scares, the EFSA seeks to achieve more transparency and 
restore public confi dence.
To this end, the Executive Director of the EFSA, Geoffrey Podger, has taken a posi-
tion in favor of the labeling approach. He explains that when GM products were clearly 
labeled in the United Kingdom, many people bought them and initially gave GMOs a 
degree of acceptability, “until commodity crops starting arriving from North America 
in which GMO and non–GMO varieties could not be differentiated.”113 The European 
opposition to GMOs did not come about because the science had changed, but rather it 
was based on ethical grounds as a reaction to being denied a choice. As a consequence, 
Dr. Podger believes that the solution to regaining the support of the European public 
is through labeling:
The great advantage of labeling is that it provides a choice. And while the people 
who insist on choice may be quite a small part of the population, they are very 
vociferous and they are often in positions of power and prominence.114
Dr. Podger sees potential for the market for GMOs to open if these products have ob-
vious advantages for consumers even in the face of some risk.115 Public perceptions, 
he notes, are open to change with new information, as long as the regulatory process 
is transparent and gives people all available information on the science. “Equally, of 
course, we are always open to new scientifi c evidence and to improving the regulatory 
process if necessary.”116
All GM products seeking to enter the EU market as food or feed must undergo an 
extensive authorization procedure, including a scientifi c safety assessment by the EFSA. 
As of 2000, twenty-two nations, including Great Britain, France, Australia, Japan, South 
Korea, and Mexico, in addition to the EU, had passed regulations that require GM food 
labeling.117 Thus, the EU and the international community continue to pursue an aggres-
sive policy of caution in the regulation of bioengineered foods and food products.118
110 Id.
111 Id.
112 Id.
113 Id.
114 Id.
115 Id.
116 Id.
117 See Press Release, Oregon State Univ. (OSU), OSU Economist Estimates Cost of GM Food Labels 
(Oct. 23, 2000), available at http://www.biotech-info.net/label_cost.html. 
118 See THE NATIONAL FOREIGN TRADE COUNCIL, INC., LOOKING BEHIND THE CURTAIN: THE GROWTH OF TRADE 
BARRIERS THAT IGNORE SOUND SCIENCE (May 2003), available at http://www.wto.org/english/forums_e/ngo_e/
posp47_nftc_looking_behind_e.pdf.
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IV. A LOOK AT EXISTING U.S. LAW
In contrast to the stringent premarket approval process, mandatory labeling, and 
moratoriums in Europe and the international community, the United States has not 
developed a regulatory scheme of special safeguards for GMOs because the U.S. gov-
ernment does not recognize biotechnology as posing special risks. As a consequence, 
U.S. regulation of biotechnology food products does not differ fundamentally from the 
regulation of conventional food products. The United States uses health and safety laws 
written prior to the development of modern biotechnology to review genetically engi-
neered products. To date, the United States has not issued any new legislation for these 
products.119 Under the 1986 Coordinated Framework for Regulation of Biotechnology, 
three agencies primarily share the regulatory oversight responsibility for these products: 
USDA and its agencies, which regulate and monitor the use of biotechnology for agri-
culture, restricting, among other things, the addition of potential plant pests “altered or 
produced through genetic engineering”;120 the Environmental Protection Agency (EPA), 
which approves new pesticidal and herbicidal substances; and FDA, which has legal 
authority with respect to food safety and labeling. Depending on its characteristics, a 
product may be subject to review by one or more of these agencies.
The agencies apply existing food safety and environmental protection laws and regula-
tions to GM products and approve their entry into the market based on the characteristics 
of the end product rather than on the process by which a product is made. Thus, it is 
immaterial that the product originated from genetic engineering.121 Each agency draws 
on its own perspective and area of concern. For example, USDA regulates fi eld testing 
and examines possible environmental consequences as to plant pests, other organisms, 
and weediness characteristics (e.g., the potential to become a weed through ease of seed 
dispersal); EPA considers the health effects by assessing allergenicity and digestibility, 
the environmental fate such as the potential for cross-pollination, and the effects on 
nontarget organisms, particularly whether the introduced pesticidal substance is toxic 
to wildlife; and FDA asks the developer voluntarily to address issues of food safety 
and allergenicity, examining “whether the introduction of the genetic material into the 
plant caused any unexpected effects by analyzing the composition of the food, paying 
particular attention to levels of known toxicants and signifi cant nutrients.”122 However, 
119 United States Regulatory Agencies Unifi ed Biotechnology Website, Frequently Asked Questions, 
http://usbiotechreg.nbii.gov/FAQRecord.asp?qryGUID=2 (last visited May 13, 2006). For a compilation 
of the laws currently used to regulate the products of modern biotechnology and the regulations developed 
under these statutes (the Plant Protection Act, the Federal Food, Drug, and Cosmetic Act (FDCA), the Fed-
eral Insecticide, Fungicide, and Rodenticide Act, and the Toxic Substances Control Act), see United States 
Regulatory Agencies Unifi ed Biotechnology Website, U.S. Laws and Regulations, http://usbiotechreg.nbii.
gov/lawsregsguidance.asp (last visited May 13, 2006). See also 1986 Coordinated Framework for Regulation 
of Biotechnology, 51 Fed. Reg. 23,302 (June 26, 1986).
120 See, e.g., Introduction of Organisms and Products Altered or Produced Through Genetic Engineer-
ing Which are Plant Pests or Which There is Reason to Believe are Plant Pests, 7 C.F.R. § 340 (1997). For 
example, USDA’s Biotechnology Regulatory Services, which is a branch of the Animal and Plant Health 
Inspection Service, “regulates the fi eld testing, movement, and importation of genetically engineered (GE) 
organisms that are known to be, or could be plant pests.” Biotechnology Regulatory Services, Introduction 
to Biotechnology Regulatory Services of the Animal & Plant Health Inspection Service, http://www.aphis.
usda.gov/brs/ (last visited May 13, 2006).
121 Stamps, supra note 48, at 5-6.
122 U.S. Dep’t of State, Food Safety: Regulating Plant Agricultural Biology in the United States (Oct. 
2000), available at http://usinfo.state.gov/products/pubs/archive/biotech/ (outlines regulatory procedures 
from the time a scientist has an idea for a potentially marketable bioengineered plant product to when the 
product appears in the local food market).
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“each agency … relies on industry data and rarely completes its own independent 
experiments comparing different foods.”123
U.S. regulations do not mandate labeling of GM foods, but instead recommend vol-
untary labeling of bioengineered foods and request that companies notify FDA of their 
intent to market GM foods at least 120 days before launch.124 The inquiry focuses on 
whether the GM foods are substantially equivalent to their parent crops.125 If so, only 
the general labeling requirements for all foods would apply. For all foods, section 403(i) 
of the Federal Food, Drug, and Cosmetic Act (FDCA) requires that “each food bear a 
common or usual name or, in the absence of such a name, an appropriately descriptive 
term.” In addition, under section 201(n), the label of the food must reveal all material 
facts about the food.126 In its 1992 policy statement on foods developed from new plant 
varieties including bioengineered foods, FDA emphasized that, while the agency was 
not establishing special labeling requirements for bioengineered foods as a class of 
foods, this preexisting scheme would apply:
Thus, consumers must be informed, by appropriate labeling, if a food derived 
from a new plant variety differs from its traditional counterpart such that the 
common or usual name no longer applies to the new food, or if a safety or 
usage issue exists to which consumers must be alerted.127
FDA offers as an example a tomato that has had a peanut protein introduced into it. If 
“there is insuffi cient information to demonstrate that the introduced protein could not 
cause an allergic reaction in a susceptible population,” a warning on the label “would 
be required to alert consumers who are allergic to peanuts.”128 This information would 
be “a material fact” whose omission may make the label of the tomato misleading under 
section 403(a) of the FDCA.129
From FDA’s perspective, biotechnologically-produced products are seen as substan-
tially equivalent to conventional food products because, in the agency’s view, there is no 
scientifi c basis to presuppose that biotech foods are more risky or substantially different 
from other food products. FDA states in its regulations that the agency
believes that the new techniques are extensions at the molecular level of 
traditional … plant breeding. The agency is not aware of any information 
123 CRS REPORT, supra note 24.
124 Ahmed, supra note 12, at 215. See, e.g., Premarket Notice Concerning Bioengineered Foods, 21 
C.F.R. Parts 192 and 592 (2001), available at http://www.cfsan.fda.gov/~lrd/fr010118.html.
125 There is no defi nition provided in the regulations for substantial equivalence and no clear and 
universal guidelines stipulating what to test and how similar the items in question should be. It has been 
said that the amount of comparative data required to establish substantial equivalence involved a somewhat 
subjective judgment. ROYAL SOCIETY UPDATE, supra note 18. As a result, this controversial concept has been 
disfavored in Europe where the capability to classify a novel food as being substantially equivalent no longer 
justifi es a lack of safety assessments.
126 21 U.S.C. § 343(i); id. § 343(a); id. § 321(n) (2005); see also Letter from Catalina Ferre-Hockensmith, 
Dep’t of Health and Human Servs. (HHS), Div. of Standards and Labeling Regulations, to Vircher B. Floyd 
(Sept. 17, 2002), available at http://www.fda.gov/ohrms/DOCKETS/dailys/02/Sep02/092502/8002a5c7.
pdf.
127 Statement of Policy: Foods Derived From New Plant Varieties, 57 Fed. Reg. 22,984, 22,991 (May 
29, 1992).
128 Id. For critiques of this regime, see, for example, Lara Beth Winn, Special Labeling Requirements 
for Genetically Engineered Food: How Sound Are the Analytical Frameworks Used by the FDA and Food 
Producers?, 54 FOOD & DRUG L.J. 667 (1999); Carl R. Galant, Comment, Labeling Limbo: Why Genetically 
Modifi ed Foods Continue to Duck Mandatory Disclosure, 42 HOUS. L. REV. 125 (2005).
129 21 U.S.C. § 321(n), cited in Statement of Policy: Foods Derived From New Plant Varieties, 57 Fed. 
Reg. at 22,991.
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showing that foods derived by these new methods differ from other foods in 
any meaningful or uniform way, or that, as a class, foods developed by the 
new techniques present any different or greater safety concern than foods 
developed by traditional plant breeding. For this reason, the agency does not 
believe that the method of development of a new plant variety (including the 
use of new techniques including [rDNA] techniques) is normally material 
information … and would not usually be required to be disclosed in the label-
ing for the food.130
Accordingly, if GM soy contains the same nutritional and dietary content as its pre-
decessor, FDA does not require that it be labeled as a biotechnologically altered food. 
This policy was reaffi rmed by FDA in 2001 in its Draft Guidance for Industry allowing 
voluntary labeling indicating whether foods have or have not been developed using 
bioengineering.131
FDA’s treatment of GM foods contrasts with its handling of the irradiation of food, 
which was a food processing technology considered by the agency to be a “material fact” 
necessary to disclose to consumers through labeling. FDA approved the use of ionizing 
radiation on various foods under specifi c conditions.132 Although FDA determined that 
“there is no concern about the safety of such treatment,” the agency concluded that la-
beling of irradiated foods was necessary because such processing is a material fact that 
must be disclosed to the consumer to prevent deception. FDA determined that irradiation 
is a form of processing that can produce signifi cant changes in certain characteristics 
of a food, such as the organoleptic (e.g., taste, smell, texture) or holding properties, in 
a manner that is not obvious to the consumer in the absence of labeling. That is, in the 
absence of labeling indicating that the food has been irradiated, the implied representa-
tion to consumers is that the food has not been processed.133
FDA thus required that the label and labeling of retail packages or displays of foods 
treated with ionizing radiation include both the radura logo (the international symbol 
that indicates radiation treatment) and a disclosure statement (either “Treated with 
radiation” or “Treated by irradiation”‘) in addition to information required by other 
regulations.134 In mandating a disclosure on all irradiated foods, FDA was cognizant of 
widespread consumer concerns about food irradiation. According to the agency, “the 
large number of consumer comments requesting retail labeling attest to the signifi cance 
placed on such information by consumers.”135
Supporters of GM food labeling point to FDA’s irradiated foods analysis as being 
applicable as well to GM foods, reasoning that “the absence of an affi rmative statement 
that a food had been genetically modifi ed would be viewed as an implied representation 
to consumers that it has been grown by traditional means.”136 In Alliance for Bio-Integ-
130 Statement of Policy: Foods Derived From New Plant Varieties, 57 Fed. Reg. at 22,991.
131 CFSAN, FDA, Draft Guidance for Industry: Voluntary Labeling Indicating Whether Foods Have or 
Have Not Been Developed Using Bioengineering (Jan. 2001) [hereinafter FDA, Draft Guidance on Voluntary 
Labeling], available at http://vm.cfsan.fda.gov/~dms/biolabgu.html.
132 Irradiation in the Production, Processing and Handling of Food, 21 C.F.R. § 179.26 (2003).
133 Irradiation in the Production, Processing, and Handling of Food, 21 C.F.R. Part 179, 64 Fed. Reg. 
7834 (Feb. 17, 1999), citing Irradiation in the Production, Processing, and Handling of Food, Final Rule, 51 
Fed. Reg. 13,376 (Apr. 18, 1986); Irradiation in the Production, Processing, and Handling of Food; Final 
Rule, 53 Fed. Reg. 12, 757 (Apr. 18, 1988).
134 21 C.F.R. § 179.26(c)(1), (2).
135 51 Fed. Reg. at 13,388.
136 Emily Marden, Risk and Regulation: U.S. Regulatory Policy on Genetically Modifi ed Food and 
Agriculture, 44 B.C.L. REV. 733, 763 (2003); see also Frederick Degnan, Food Labeling and the Right-to-
Know, 52 FOOD & DRUG L.J. 49 (1997).
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rity v. Shalala,137 a group of concerned citizens sued FDA claiming that the agency’s 
refusal to require labeling and safety testing raises health and environmental concerns 
and makes it diffi cult to comply with religious dietary laws. The suit identifi ed thirty-
six genetically modifi ed foods being consumed daily without the knowledge of U.S. 
consumers. Seeking to apply the food-processing reasoning used for irradiated foods, 
the plaintiffs demanded that FDA institute mandatory labeling of GM foods on the 
grounds that genetic alteration made material changes (i.e., safety, allergenicity risks) 
to foods. The plaintiffs took the position that the process of being genetically modifi ed 
was itself a material fact. The court rejected both of these arguments, however, and 
affi rmed FDA’s position.138
In November 2004, FDA proposed a Draft Guidance for Industry for New Plant 
Varieties Intended for Food Use “to address the possibility that material from a new 
plant variety intended for food use might inadvertently enter the food supply before its 
sponsor has fully consulted with the [FDA].”139 This draft guidance provides a scientifi c 
framework in which to evaluate the food safety of new nonpesticidal proteins produced 
in bioengineered plants,140 and encourages developers to submit to FDA their evaluation 
of the food safety of their new protein. FDA recognized the possibility that
[s]cientifi c advances are expected to accelerate over the next decade, leading 
to the development and commercialization of a greater number and diversity 
of bioengineered crops. As the number and diversity of fi eld tests for bioengi-
neered plants increase, the likelihood that cross-pollination due to pollen drift 
from fi eld tests to commercial fi elds and commingling of seeds produced during 
fi eld tests with commercial seeds or grain may also increase.141
FDA recommends that sponsors and developers of new plant varieties intended for food 
use “consult with FDA about their evaluation of the food safety of any new proteins 
produced in these plants prior to the stage of development where the new proteins might 
inadvertently enter the food supply.”142 The agency made it clear, however, that any con-
cern related to such material entering the food supply would be limited to the possibility 
that the new protein could cause an allergic reaction in susceptible individuals or could 
be a toxin in people or animals.143 Additionally, FDA stressed that this draft guidance 
137 Alliance for Bio-Integrity v. Shalala, 116 F. Supp. 2d 166, 178 (D.D.C. 2000).
138 Id.
139 FDA, FDA Talk Paper, FDA Proposes Draft Guidance for Industry for New Plant Varieties Intended 
for Food Use (Nov. 19, 2004), available at http://www.fda.gov/bbs/topics/ANSWERS/2004/ANS01327.
html; Draft Guidance for Industry: Recommendations for the Early Food Safety Evaluation of New Non-
Pesticidal Proteins Produced by New Plant Varieties Intended for Food Use, 69 Fed. Reg. 68,381 (Nov. 24, 
2004); see also HHS, HHS News, FDA to Strengthen Pre-Market Review of Bioengineered Foods (May 3, 
2000), available at http://www.cfsan.fda.gov/~lrd/hhbioen2.html (announcing FDA’s “plans to draft labeling 
guidance to assist manufacturers who wish to voluntarily label their foods being made with or without the 
use of bioengineered ingredients”).
140 This guidance concerns developers of new plant varieties that are intended for food use, describing 
procedures for the early food safety evaluation of such new nonpesticidal proteins. FDA notes that, because 
EPA is responsible for assessing the safety of pesticides including plant-incorporated protectants, those 
proteins are not subject to FDA review or this guidance. See FDA, Guidance for Industry: Recommenda-
tions for the Early Food Safety Evaluation of New Non-Pesticidal Proteins Produced by New Plant Varieties 
Intended for Food Use (2004) [hereinafter FDA, Guidance for Industry, Recommendations for Early Food 
Safety Evaluation], available at http://www.cfsan.fda.gov/~dms/bioprgui.html.
141 FDA Talk Paper, supra note 139.
142 FDA, Guidance for Industry, Recommendations for Early Food Safety Evaluation, supra note 140.
143 Draft Guidance for Industry: Recommendations for the Early Food Safety Evaluation of New Non-
Pesticidal Proteins Produced by New Plant Varieties Intended for Food Use, 69 Fed. Reg. at 68,382. 
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does not establish legally enforceable responsibilities, but “describe[s] the agency’s 
current thinking on a topic and should be viewed only as recommendations … .”144
Note that the U.S. approach differs greatly from the international approach embodied 
by the Codex principles and Cartagena Protocol, most signifi cantly by not adopting 
the precautionary principle that would require premarket approval conditioned upon 
a case-by-case risk assessment to consider the intended and unintended effects of the 
GM product before its release.145 In promulgating its regulatory scheme, FDA appears 
to have given little weight to the scientifi c uncertainty and risks recognized by its EU 
counterparts as inherent in GMOs.146 FDA’s regulations go no farther than recom-
mendations to the industry of communication with the agency and, unlike the EU and 
international regulations, do not require disclosure of GM processes to the consumer. 
The absence of mandatory labeling and monitoring, as well as a premarket approval 
process, stands in stark contrast to the approach overseas.
Efforts to strengthen the U.S. government’s control of GM foods through legislation 
have been unsuccessful thus far. In May 2002, Representative Dennis J. Kucinich (D-OH) 
introduced H.R. 4814, the Genetically Engineered Food Right to Know Act, a bill that 
would require labeling of biotechnology food products.147 The purpose of the bill was 
“[t]o amend the Federal Food, Drug, and Cosmetic Act, the Federal Meat Inspection 
Act, and the Poultry Products Inspection Act to require that food that contains a geneti-
cally engineered material, or that is produced with a genetically engineered material, 
be labeled accordingly.”148 Although H.R. 4814 gained thirty-eight cosponsors, the bill 
died in a subcommittee.149
H.R. 4814 was one of fi ve bills introduced by Rep. Kucinich that sought to expand 
the regulation of agricultural biotechnology. H.R. 4812, the Genetically Engineered 
Crop and Animal Farmer Protection Act, would “provide additional protections for 
farmers and ranchers that may be harmed economically by genetically engineered 
seeds, plants, or animals,” establishing a Farmer’s Bill of Rights “to ensure fairness for 
farmers and ranchers in their dealings with biotechnology companies that sell geneti-
cally engineered seeds, plants, or animals.”150 Among these protections, the bill would 
require disclosure by the biotechnology companies of the legal and environmental 
Based on [the] EPA’s fi nding that the genetically engineered proteins in Bt 10 are safe, the extremely 
low levels of Bt 10 corn in the food and feed supply, and the fact that corn does not contain any 
signifi cant natural toxins or allergens, [the] FDA has concluded that the presence of Bt 10 corn 
in the food and feed supply poses no safety concerns.
CFSAN, FDA, U.S. Food and Drug Administration’s Statement on Bt 10 (Apr. 27, 2005), available at 
http://www.cfsan.fda.gov/~lrd/biobt10.html.
144 FDA, Guidance for Industry, Recommendations for Early Food Safety Evaluation, supra note 
140.
145 In fact, in discussions of the Codex, the United States has consistently battled with Europeans over 
their incorporation of the precautionary principle into regulation of GM technology. See, e.g., Marden, supra 
note 136, at 786 (citing FDA Public Meeting on the Codex Ad Hoc Intergovernmental Task Force on Food 
Derived from Biotechnology (Dec. 15, 1999)).
146 The United States has vigorously resisted “any efforts to regulate GM technology based on the devel-
opment process, or on grounds of potential health or environmental risks,” opposing the European Commission 
and others in the drafting of the Convention on Biological Diversity, which “permit[ted] non-scientifi cally 
based measures to justify exclusion of GM products from entry into a country.” Id. at 786-87.
147 Genetically Engineered Food Right to Know Act, H.R. 4814, 107th Cong. (2002).
148 Id.
149 H.R. 4814 was referred to the House Subcommittee on Farm Commodities and Risk Management 
on June 4, 2002. Id.; see also Pew Initiative on Food and Biotechnology, Factsheet, United States H.R. 4814 
(May 2005), http://pewagbiotech.org/resources/factsheets/legislation/bill.php?LegislationID=167.
150 Genetically Engineered Crop and Animal Farmer Protection Act of 2002, H.R. 4812, 107th Cong. 
(2002).
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risks that the use of the genetically engineered seeds, plants, or animals may pose to 
the purchaser; prevent noncompetitive practices involving technology fees; preclude 
the biotechnology company from limiting liability for harm that may result from the 
release of genetically engineered material into the environment; and prohibit the sale of 
certain nonfertile plant seeds (a seed that is genetically engineered to produce a plant 
whose seeds are not capable of reproduction).
H.R. 4813, the Genetically Engineered Food Safety Act, would “amend the Federal 
Food, Drug, and Cosmetic Act with respect to the safety” of biotech foods.151 This bill 
explicitly recognized that “genetic engineering is an artifi cial gene transfer process 
wholly different from traditional breeding” and considered adding new genes into a food 
as comparable to adding a food additive, thus requiring an analysis of safety factors:
Given the consensus among the scientifi c community that genetic engineer-
ing can potentially introduce hazards, such as allergens or toxins, genetically 
engineered foods need to be evaluated on a case-by-case basis and cannot be 
presumed to be generally recognized as safe.152
H.R. 4813 would require that all GMOs be determined safe for human consumption prior 
to release in the market, and would give FDA the right to impose independent testing 
and to seek input from the National Academy’s Institute of Medicine. Further, the bill 
would authorize citizen suits for genetic food additives in the event of noncompliance 
with these provisions.153
H.R. 4815, the Real Solutions to World Hunger Act, would restrict genetically engi-
neered exports to GMOs approved in the United States and by the importing nation.154 
By its terms, the bill asserted that “[t]he need for mandatory labeling, safety testing, and 
environmental reviews of genetically engineered foods do not constitute obstacles to the 
cessation of world hunger.”155 The stated purpose was “[t]o ensure that efforts to address 
world hunger through the use of [biotech] animals and crops actually help developing 
countries and people, while protecting human health and the environment … .”156 H.R. 
4815 would support funding for international research that promotes the development of 
sustainable agriculture techniques with minimum artifi cial inputs to meet the food and 
fi ber needs of developing countries.
Finally, H.R. 4816, the Genetically Engineered Organism Liability Act, would hold 
biotechnology companies liable to any party for injuries caused by the release of a 
genetically engineered organism into the environment.157 The list of potential injuries 
included crop failures suffered by farmers, cross pollination of neighboring farms, and 
increased insect resistance, as well as health and environmental impacts on consumers.158 
All of these bills were referred to subcommittees with no further action.
Likewise, in the U.S. Senate, Senator Richard Durbin (D-IL) in October 2002 in-
troduced S. 3095, the Genetically Engineered Foods Act (GEFA), a bill “to amend the 
Federal Food, Drug, and Cosmetic Act to require premarket consultation and approval 
with respect to genetically engineered foods, and for other purposes.”159 This legisla-
151 Genetically Engineered Food Safety Act of 2002, H.R. 4813, 107th Cong. (2002).
152 Id.
153 Id.
154 Real Solutions to World Hunger Act of 2002, H.R. 4815, 107th Cong. (2002).
155 Id.
156 Id.
157 Genetically Engineered Organism Liability Act of 2002, H.R. 4816, 107th Cong. (2002).
158 Id.
159 Genetically Engineered Foods Act, S. 3095, 107th Cong. (2002).
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tion would require FDA to review and approve all genetically engineered foods prior 
to introduction into interstate commerce. It would authorize approval exemptions for 
a food category deemed not to be a food safety risk and would provide for trade secret 
protection. Specifi cally, the GEFA would direct the Secretary of Health and Human Ser-
vices (HHS) to establish 1) a program to test for the presence of genetically engineered 
ingredients in food from all stages of agricultural production to retail distribution and 
2) a genetically engineered food registry that contains the regulatory status of all such 
approved foods. S. 3095 also applied provisions respecting adulterated drugs and devices 
to genetically engineered animals; set forth application criteria, including provisions for 
protection of trade secrets and environmental assessments; and incorporated prohibitions 
against unlawful use of trade secret information and adulterated food. There apparently 
was no action on this bill, as it died in committee.160
Congress does not appear to be supporting initiatives to address food safety concerns 
and to tighten the regulatory process for bioengineered food in the United States. In 
the 108th Congress (2003-2004), thirteen bills and two resolutions specifi cally ad-
dressing agricultural biotechnology were introduced. Of those, only two nonbinding 
resolutions—supporting the Administration’s efforts to bring a complaint against the 
European Union for its restrictions on GM crops—passed (H.R. Res. 252 and S. Res. 
154).161 The stated purpose of these resolutions was to express the support of the House 
of Representatives and the Senate for the United States “in its efforts within the World 
Trade Organization (WTO) to end the European Union’s protectionist and discrimina-
tory trade practices of the past fi ve years regarding agriculture biotechnology.”162 Each 
resolution “supports and applauds the efforts of the Administration on behalf of the 
Nation’s farmers, challenging the long-standing, unwarranted moratorium imposed by 
the European Union on the approval of agriculture biotechnology products and encour-
ages the President to continue to press this issue … .”163
With the U.S. Congress continuing to take relatively little action on biotechnology-
focused legislation to alter the way GM foods are regulated,164 state legislatures have 
come forward as the main venue for issues pertaining to agricultural biotechnology.165 
In the 2003-2004 legislative session, 170 pieces of legislation (156 bills and fourteen 
resolutions) were introduced in thirty-fi ve different states, representing a seven percent 
increase over the amount of legislation introduced in thirty-nine state legislatures in 
2001-2002.166 This increase indicates a growing trend that agricultural biotechnology 
issues generate a high level of interest among state legislators and their constituents.
The state legislation can be classifi ed into several broad categories: regulating biotech 
crops and animals, labeling, liability and agricultural contracts, studies or task forces, 
supporting the technology, implementing moratoria, or criminalizing crop destruction. 
Of the thirty-seven pieces of legislation that passed in 2003-2004, a majority (21) fell 
160 Id. On the day it was introduced in the Senate, it was read twice and referred to the Committee on 
Agriculture, Nutrition, and Forestry.
161 H.R. Res. 252, 108th Cong. (2003) (introduced by Rep. Roy Blunt, R-MO); S. Res. 154, 108th 
Cong. (2003) (introduced by Sen. Jim Talent, R-MO); see also Pew Initiatives on Food and Biotechnology, 
Factsheet, State Legislative and Local Activities Related to Agricultural Biotechnology Continue to Grow in 
2003-2004 (May 2005), http://pewagbiotech.org/resources/factsheets/legislation/factsheet.php [hereinafter 
PEW Legislative Activities].
162 H.R. Res. 252.
163 S. Res. 154, 108th Cong. (2003).
164 A review of the current legislative session (109th Congress, 2005-2006) fi nds no pending bills or 
resolutions involving GMOs or food biotechnology. See The Library of Congress: THOMAS, http://thomas.
loc.gov/ (last visited May 13, 2006).
165 PEW Legislative Activities, supra note 161.
166 Id.
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into the category of “supporting biotechnology.” Nationally, there was a large increase 
in the number of bills introduced that support biotechnology, particularly as a tool for 
economic development. In 2004, two states passed legislation that would “assert state 
preeminence over agricultural biotechnology and prevent local initiatives from counter-
ing state authorities.”167
One trend in 2003-2004 was the increase in legislation addressing “novel” applica-
tions of agricultural biotechnology, beyond the corn, cotton, and soybeans modifi ed 
for herbicide or insect resistance that have proliferated in the United States: “The next 
generation of agricultural biotechnology products is likely to include new food or feed 
crops (possibly alfalfa, wheat, coffee, or rice); transgenic fi sh or other aquatic organ-
isms; transgenic crops and livestock genetically modifi ed to produce human therapeutics 
or industrial compounds; and other genetically modifi ed animals.”168 Regional issues 
appear to dominate the kinds of legislation introduced by state lawmakers. “But some 
state legislation has also addressed labeling and the safety of new products such as 
transgenic fi sh—areas much more commonly handled by federal agencies.”169 State 
legislatures across the nation passed seven bills regulating biotech crops or animals,170 
three bills addressing labeling,171 one bill on the subject of liability and agricultural 
contracts,172 four pieces of legislation in the study/task force category,173 and one bill 
imposing a moratorium.174 These developments potentially raise issues of a constitu-
tional dimension, such as preemption and the Commerce Clause.175 In the absence of 
a comprehensive system of federal legislation, these state and local restrictions could 
result in “a patchwork of inconsistent regulatory requirements … .”176
V. A MODEL OF CAUTION: LABELING AND MONITORING
Despite the benefi ts of biotechnology, the safety issues from unintended and unknown 
risks and scientifi c uncertainty necessitate a more effective approach to risk assessment 
in the United States. Without transparency as to the presence of GM products in food, 
informed choice cannot be realized. This lack of information also impedes the develop-
ment of biotechnology in the long run. A report by the Atlantic Council of the United 
167 Id.
168 Id.
169 Id. 
170 See Arizona HB2615, Michigan SB226, Michigan SB227, Michigan SB228, Michigan SB229, 
Pennsylvania HB2387, and South Dakota HB1237, cited in PEW Legislative Activities, supra note 161.
171 See Vermont HB 777, Pub. Act No. 97 (2004) (requires all GM seed to be labeled with information 
describing the trait; requirements for safe handling, storage, transport, and use; and information about the 
manufacturer; all manufacturers of GM seed are required to report to the secretary the quantities sold annu-
ally); Minnesota SF 2843 (passed Mar. 15, 2004, but presumed dead in Committee) (provides guidelines for 
voluntary labeling of dairy products produced from cows not treated w rBGH (rBST) and mandates that dairy 
products derived from cows that have been treated with rBGH be labeled as such); Maine HP 1149 (2003) 
(imposes a civil violation for any manufacturer, distributor, processor, wholesaler or retailer who falsely labels 
any product such as commercial feed as made without genetic engineering or bioengineering).
172 See Illinois HB 264, cited in PEW Legislative Activities, supra note 161.
173 See Hawaii SB 837, Illinois SR 89, Montana SJ 8, and New Mexico SMR 62, cited in PEW Legisla-
tive Activities, supra note 161.
174 A moratorium on transgenic fi sh passed in California. California SB 245, ch. 871, Statutes of 2003 
(2003), cited in PEW Legislative Activities, supra note 161.
175 See Eric Lasker, Federal Preemption and State Anti-“GM” Food Laws, 20 LEGAL BACKGROUNDER 
1 (2005) (confl ict between favorable federal law and restrictive state legislative laws may raise preemption 
issues); Eric Lasker, FDA Position on Federal Preemption Consistent with Law & Public Health, 20 LEGAL 
BACKGROUNDER 1 (2005) (FDA asserting in court proceedings that the agency’s labeling of FDA-regulated 
products, including prescription drugs, should be given preemptive effect over state law).
176 PEW Legislative Activities, supra note 161.
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States found that “[c]onsumer confi dence is the most important determinant of any future 
market [in] … biotechnology.”177 The Council concluded that a credible scientifi c risk 
assessment process is essential, and that some form of labeling and traceability may be 
useful in providing consumers with information and choice.178
With regard to GMOs, the most prevalent view is the demand for information and for 
choice. According to recent polls, 94.6% of Europeans want the right to choose whether 
or not they eat food that has been genetically modifi ed.179 Other studies in Japan and 
Europe indicated a decline of confi dence in the biotechnology product.180 Bioengineered 
food will face increasing resistance from consumers worldwide until transparent and 
reliable information, as well as evidence of the potential risks, can be provided.181
A similar survey in the United States showed that almost two-thirds of the respon-
dents were very concerned or somewhat concerned about the food safety problem of 
GM products. 182Among the U.S. consumers recently surveyed, there appears to be little 
awareness concerning the genetic modifi cation of agricultural and food products.183 Only 
two in fi ve Americans (forty-one percent) say that they realize that genetically modifi ed 
food products currently are for sale in supermarkets.184 Even so, over seventy-fi ve per-
cent of Americans stated that the potential danger from genetic modifi cation is so great 
that strict regulations are necessary; yet sixty-three percent believe that the government 
does not have the tools to regulate GMOs properly.185 Nine out of ten Americans said 
that GM foods should be labeled as such, although only about half said they actually 
would take time to look for foods labeled as not being genetically modifi ed.186 (This last 
point should be welcome news for the biotechnology industry, which may be concerned 
about the impact of labeling on sales.) In another poll, ninety-three percent of Ameri-
cans agreed that the federal government should require labels identifying genetically 
modifi ed or bioengineered foods. “Such near unanimity in public opinion is rare.”187 
Even among American farmers, “90 [percent] … . support labels on biotech products 
if they are scientifi cally different from conventional foods and 61 [%] support labels 
on biotech products even if not scientifi cally different.”188 The increased attention from 
177 DAVID AARON ET AL., RISK AND REWARD: U.S.-EU REGULATORY COOPERATION ON FOOD SAFETY AND THE 
ENVIRONMENT (Nov. 2002), available at http://www.acus.org/Publications/policypapers/TransatlanticRela-
tions/Risk%20and%20Reward.pdf. 
178 Id.
179 EUROPEAN COMMISSION RESEARCH DIRECTORATE-GENERAL, EUROPEANS, SCIENCE AND TECHNOLOGY (Dec. 
2001), available at http://europa.eu.int/comm/public_opinion/archives/eb/ebs_154_en.pdf.
180 Pan, supra note 1, at 232 (citing D. Dickson, Public Attitudes to Biotechnology: Where are They 
Heading?, Paper presented at the New Biotechnology Foods and Crops: Science Safety and Society Bangkok 
Conference, (July 10-12, 2001)).
181 Id.
182 Id.
183 WILLIAM K. HALLMAN ET AL., PUBLIC PERCEPTIONS OF GENETICALLY MODIFIED FOODS: AMERICANS KNOW 
NOT WHAT THEY EAT (Food Policy Inst., Mar. 15, 2002), available at http://www.foodpolicyinstitute.org/docs/
reports/Public%20Perceptions%20of%20Genetically%20Modifi ed%20Foods.pdf.
184 Id.; see also Pew Initiative on Food and Biotechnology, Public Sentiment About Genetically Modifi ed 
Food (Nov. 2005 Update), available at http://pewagbiotech.org/research/2005update/ (While knowledge of 
genetically modifi ed foods has increased to 41%, fewer—25%—believe they have or are likely—40%—to 
eat GM foods. Those who are most informed about GM foods also oppose their introduction into the food 
supply, with 54% opposed among those who have heard “a great deal” about GM foods.)
185 Id.
186 Id.
187 The GE Food Alert Campaign Center, American Public Opinion Polls on GE Foods, http://www.
gefoodalert.org/News/news.cfm?News _ID=3151 (last updated Feb. 1, 2002) (citing an ABCNews.com 
poll, June 2001).
188 Id. (citing Farm Foundation/Kansas State Univ., Survey of Farms Throughout the United States 
(Sept. 2001)).
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the public and erosion of consumer confi dence should compel regulators and legislators 
to reexamine current policies.
In the past, FDA recognized this mandate from the people but rejected mandatory 
labeling based on the restraints of the agency’s own regulatory scheme and FDA’s nar-
row reasoning as to the role of undetermined risks, stating that
[m]ost of the comments that addressed labeling requested mandatory disclosure 
of the fact that the food or its ingredients was bioengineered or was produced 
from bioengineered food. However, these comments did not provide data or 
other information regarding consequences to consumers from eating the foods 
or any other basis for FDA to fi nd under section 201(n) of the act that such 
a disclosure was a material fact. Many of the comments expressed concern 
about possible long term consequences from consuming bioengineered foods, 
but they did not contend that any of the bioengineered foods already on the 
market have adverse health effects. The comments were mainly expressions 
of concern about the unknown.189
In reviewing the more than 50,000 written comments about its policy, FDA did acknowl-
edge “there was general agreement that providing more information to consumers about 
bioengineered foods would be useful.”190 FDA’s position rejecting mandatory labeling 
based mainly on “concerns about the unknown” contrasts directly with the precaution-
ary principle embodied in the Cartagena Protocol, which does not allow the “[l]ack of 
certainty due to insuffi cient relevant scientifi c information and knowledge” to prevent 
restrictions on imports to avoid these “potential adverse effects.”191 The ultimate ques-
tion is who bears the burden of proving that these substances are not hazardous—the 
companies before approval or the consumers who fear the potential hazards. Science 
is fallible—who do we want to bear the risk of as-yet undetected hazards? If the U.S. 
government does not require a rigorous pre-approval process as do the Europeans, at 
the very least it should require the food to be labeled so that consumers can individu-
ally make this choice. Moreover, there can then be some chance of removal from the 
market if, through the development of scientifi c assessment techniques and long-term 
studies, problems are discovered later.
Countries that have introduced mandatory labeling legislation for GM foods have 
done so to give their consumers a choice in selecting foods according to their comfort 
level.192 Transparency can be ensured only by requiring labeling and traceability of 
food products derived from GM plants at all stages of production and distribution.193 
Realizing the potential of agricultural biotechnology in the United States and world-
wide will require activist policy reform rather than a laissez-faire approach. It has been 
suggested that countries tailor their regulations so as to minimize harm to trade while 
also responding to consumer concerns.194 Indeed, FDA initially began investigating the 
189 FDA, Draft Guidance on Voluntary Labeling, supra note 131 (FDA’s response after reviewing more 
than 50,000 written comments about the agency’s policy regarding safety and labeling of bioengineered 
foods).
190 Id.
191 See supra note 118 and accompanying text.
192 INTERNATIONAL LIFE SCIENCES INSTITUTE, DETECTION METHODS FOR NOVEL FOODS DERIVED FROM GENETI-
CALLY MODIFIED ORGANISMS (Kevin Yates ed., 1999) (summary of a workshop held in June 1998).
193 See The Non-GMO Report, EU tightens GM food labelling requirements, supra note 105.
194 See David G. Victor & C. Ford Runge, Farming the Genetic Frontier, 81 FOREIGN AFF. 107 (2002); C. 
Ford Runge & Lee Ann Jackson, Labeling, Trade and Genetically Modifi ed Organisms (GMOs): A Proposed 
Solution (Working Paper WP99-4 Nov. 1999), http://www.gefoodalert.org/library/admin/uploadedfi les/La-
beling_Trade_and_Genetically_Modifi ed_Organi.htm [hereinafter Runge & Jackson, Labeling, Trade, and 
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use of voluntary labeling for GM products to ease tensions with trading partners such 
as the European Union.195
Industry has begun to respond as well to the perceived risks of biotechnology in 
food. Fearful of losing buyers, large food producers have underscored their acceptance 
of consumer demands for labeling and have asked suppliers to segregate fi elds, grain 
bins, and storage elevators, with some even paying a premium for non-GM crops.196 
Frito-Lay made headlines when, in response to consumer worries, the company told 
its suppliers not to use genetically altered corn.197 Additionally, farmers have expressed 
concern that markets for unmodifi ed grain could be threatened because crops such as 
maize and canola risk contamination by cross-fertilization with windborne pollen.198
In examining the regulatory options, it is important to acknowledge and evaluate the 
economic costs; however, mandatory GM labeling may not involve such prohibitive 
costs. A study by an agricultural economist at Oregon State University reported that, 
for other countries that label GM foods, the total annual costs range from twenty-three 
cents per person to about ten dollars per person, depending on the level and complex-
ity of the labeling.199 The analysis of these countries determined that the cost ranged 
from twenty-three cents a year for each consumer for labeling only those products 
made directly from genetically modifi ed foods, to $3.89 for labeling of products in 
which genetically modifi ed substances were used during production or processing. The 
estimated costs for the more extensive GM labeling options under consideration in the 
United Kingdom, New Zealand, and Australia were calculated as $3 to $10 a year per 
person.200 Moreover, the actual cost may be lower to the extent that product segregation, 
identity preservation, and labeling already are becoming routine for exporters to foreign 
markets where GM labeling is required.201 In addition, there may be reduced costs in the 
form of a signifi cantly diminished risk of liability from lawsuits, at least with respect 
to potential claims for injuries that may occur due to a failure to warn.202
Mandatory labeling of GMOs generally does incur a higher cost than voluntary 
labeling because the entire market must be segregated and labeled even though only 
a subset of producers or consumers cares about the attribute. A government’s choice 
about whether to require labeling is based in part on what proportion of their citizens 
Genetically Modifi ed Organisms]; see also C. Ford Runge & Lee Ann Jackson, Negative Labeling of Geneti-
cally Modifi ed Organisms (GMOs): The Experience of rBST, 3 AGBIOFORUM 58, 58-62 (2000).
195 CRS REPORT, supra note 24 (citing TDA Eyes Voluntary Label as Middle Ground in GMO Food 
Dispute, FDA WK., Mar. 26, 1999, at 3).
196 Haslberger, supra note 73.
197 Associated Press, No Genetically Altered Corn, Frito-Lay Tells Suppliers, SACRAMENTO BEE, Feb. 
1, 2000, available at http://www.biotech-info.net/frito_lay1.html (Frito-Lay accounts for two-thirds of 
PepsiCo sales).
198 Sally Lehrman, GM Backlash Leaves US Farmers Wondering How to Sell Their Crops, 401 NATURE, 
Sept. 9, 1999, at 107.
199 OSU Press Release, supra note 117. The entire text of the OSU study (an analysis of fi ve alternative 
options for GM labeling that range in cost and complexity) is available at http://eesc.orst.edu/agcomwebfi le/
edmat/html/em/em8817/em8817.html.
200 Id. 
201 Id. As mentioned previously, as of the date of this study, twenty-two nations, including Great Britain, 
France, Australia, Japan, South Korea, and Mexico, in addition to the European Union, had passed regulations 
that require GM food labeling. Because some U.S. food producers and exporters already separate genetically 
modifi ed foods from the rest of the foods to comply with GM labeling requirements in effect in these nations, 
the incremental cost would be less.
202 For a general discussion of liability issues, see Tana N. Vollendorf, Comment, Genetically Modifi ed 
Organisms: Someone is in the Kitchen with DNA—Who is Responsible When Someone Gets Burned?, 21 
MISS. C.L. REV. 43 (2001); A. Bryan Endres, “GMO:” Genetically Modifi ed Organism or Gigantic Monetary 
Obligation? The Liability Schemes for GMO Damages in the United States and the European Union, 22 LOY. 
L.A. INT’L & COMP. L. REV. 453 (2000).
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want information about the technology.203 As demonstrated in the surveys above, the 
U.S. consumer has now reached the point where such information is desired by a vast 
majority of the citizens and demanded by a vocal portion of these consumers and 
farmers.204 The time has come for the U.S. government to be responsive to its citizenry 
and restore consumer confi dence in the food supply—both domestic and abroad—by 
requiring the disclosure of this critical feature.
Such labeling could be either positive labels stating that “This product may contain 
GMOs”; or negative labels stating that “This product (or seed) contains no GMOs.”205 
In the past, for companies wanting to advertise products as non-GM, FDA has indicated 
that it would not allow labels like “GM-free,” “GMO-Free” or “biotech-free.” The agency 
reasoned that guaranteeing a product to be free of GM material is virtually impossible 
because to establish a threshold “would require methods to test for a wide range of ge-
netic changes at very low levels in a wide variety of foods” and “such methods are not 
available at this time”; but stated that the labels could say the food was “not developed 
using bioengineering.”206 In determining the requisite labeling, the U.S. government, 
particularly FDA, should study the effectiveness of notifi cation of the consumer, the 
potential impact on industry, and take into account international standards for uniformity 
(such as the OECD effort discussed above) in order to facilitate international trade. If 
the labeling requirements conform to a uniform international standard in their wording 
and content, the costs for industry in the global marketplace will be reduced.
For these goals to be attained there must be some form of positive labeling indicat-
ing the presence or possible presence of GMOs, in order to be an effective notifi cation 
mechanism both for consumers in the United States and importers from abroad. Voluntary 
negative labeling alone will not be adequate. A mandatory positive labeling requirement 
also will target the appropriate segment of the industry. The costs of such labeling thus 
will be borne, at least in the fi rst instance, by those in the industry who have benefi ted 
from GM technology. Some of these costs ultimately will be passed on to the consumer, 
but surveys show that the U.S. consumer fi nds this labeling to be important and the 
addition of this labeling is a choice supported by the citizenry.
As food companies adapt to changes in the regulatory climate, they will need to 
devise marketing strategies that work with labeling policies in promoting the safety 
and desirability of their products.207 Thus, the most effective labeling scheme would 
include both mandatory labels indicating those products “made with GM ingredients” 
or that “may contain genetically modifi ed ingredients,” as a necessary disclosure to 
consumers; and voluntary labeling for foods that are “not made with GM processes” or 
“not produced through bioengineering,” highlighting this feature as a positive marketing 
tool to consumers. Note that as consumer preferences shape market forces, the costs 
of these voluntary negative labels will be absorbed by the successful producers (i.e., 
factored in as increased sales). Indeed, this type of labeling already has been sought by 
203 Julie A. Caswell, Should Use of Genetically Modifi ed Organisms Be Labeled?, 1 AGBIOFORUM 22, 
24 (1998) (outlining the policy options for governments associated with the types of voluntary and mandatory 
labeling and their impact on the development of markets for foods produced with GMOs).
204 See, e.g., Luke Brussel, Engineering a Solution to Market Failure: A Disclosure Regime for Geneti-
cally Modifi ed Organisms, 34 CUMB. L. REV. 427 (2003-04).
205 Runge & Jackson, Labeling, Trade, and Genetically Modifi ed Organisms, supra note 194 (advocat-
ing negative labels for GM foods).
206 FDA, Draft Guidance on Voluntary Labeling, supra note 131 (“FDA does not have information with 
which to establish a threshold level of bioengineered constituents or ingredients in foods for the statement 
‘free of bioengineered material.’”); see also The Non-GMO Report, FDA’s New Regulations Won’t Allow 
Non-GMO, GMO-Free Label, http://www.non-gmosource.com/FDA_disallows_GMO-free_label.php (last 
visited May 13, 2006).
207 Caswell, supra note 203, at 24.
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the segments of the industry that would benefi t from its marketing impact. FDA sup-
ports such labeling as long as it is truthful and not misleading.208
In labeling the presence of GMOs, a minimum threshold level may be determined so 
that a reasonably low percentage of accidental GMO presence may be allowed before 
invoking the requirement of a mandatory positive label.209 This practical and scientifi -
cally feasible approach is refl ected in EU Directive 2001/18/EC and differs from the 
“GM free” certifi cation disfavored by FDA as misleading. Still, the requirement must 
be workable and enforceable through credible scientifi c assessment and testing.210
In addition to labeling, GM products should be subject to a rigorous system of 
pre- and postmarket monitoring. Testing does involve additional costs for the industry, 
but such testing, which FDA requires premarket in other areas such as food and color 
additives,211 is necessary to protect the public. The National Research Council report 
discussed supra proposed postmarket surveillance to identify and monitor unanticipated 
compositional changes and health effects of all altered foods, noting that the current 
safety assessments only apply to genetically engineered goods before they are put on 
the market with a focus on identifying any signifi cant differences in physical charac-
teristics of the plant. The report recommended implementing a safety assessment prior 
to and after commercialization, involving federal agencies in the determination, using 
standardized sampling methodologies, and improving tracing and tracking methods 
when warranted.212
Once monitoring is mandated in the United States, scientists will focus their ef-
forts on the development of appropriate means to detect and track GM foods and their 
components. In response to EU regulations, scientists have attempted to assess and 
improve reliable and sensitive methods for GMO detection.213 Several of these methods 
need further refi nement to surmount their limits (e.g., heating and other processes in 
food production can degrade DNA and lead to false-positive rates and disappearance 
of marker genes).214 As scientifi c research on the long-term human health and environ-
208 See FDA, Draft Guidance on Voluntary Labeling, supra note 131: 
The agency is providing the following guidance to assist manufacturers who wish to voluntarily 
label their foods as being made with or without the use of bioengineered ingredients. While the 
use of bioengineering is not a material fact, many consumers are interested in the information, and 
some manufacturers may want to respond to this consumer desire. The guidance was developed 
using information from the comments and from focus groups, as well as other resources, and is 
intended to help ensure that labeling is truthful and not misleading.
See also CFSAN, FDA, REPORT ON CONSUMER FOCUS GROUPS ON BIOTECHNOLOGY (Oct. 20, 2000), available 
at http://www.cfsan.fda.gov/~comm/biorpt.html.
209 AARON, supra note 177, at 32.
210 Id. See Council Directive 2001/18/EC, supra note 96, at art. 21, § 2.
211 See, e.g., Debra M. Strauss, Reaffi rming the Delaney Anticancer Clause: The Legal and Policy 
Implications of an Administratively Created De Minimis Exception, 42 FOOD DRUG COSM. L.J. 393 (1987) 
(analyzing the Delaney Clause of the FDCA, which prohibits the use of carcinogenic food and color addi-
tives in the food supply). 
An additive determined to be ‘safe’ will be approved for the proposed use, provided that ‘no ad-
ditive shall be deemed to be safe if it is found to induce cancer when ingested by man or animal, 
or if it is found, after tests which are appropriate for the evaluation of the safety of food additives, 
to induce cancer in man or animal.
Id. at 393 (citing 21 U.S.C. § 348(c)(3)(A) (2005)).
212 NRC SAFETY, supra note 3, at 3; see supra notes 66 to 71 and accompanying text.
213 See, e.g., Ahmed, supra note 12 (discussing methods for GMO detection, including “protein- and 
DNA-based methods employing western blots, enzyme-linked immunosorbant assay, lateral fl ow strips, 
Southern blots, qualitative-, quantitative-, real-time- and limiting dilution-PCR methods;” and new approaches 
such as near-infrared spectrometry); Pan, supra note 1, at 232.
214 Ahmed, supra note 12 (proposing a tiered approach combining several methods of detection to 
counteract these limitations); Pan, supra note 1, at 230.
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mental effects of bioengineered food progresses, the postmarket monitoring of products 
containing GMOs will be critical in tracing, in the event that it becomes necessary to 
withdraw such products from the market and food chain.
Of signifi cant concern to U.S. producers is “the fact that U.S. farm, grain storage, 
and transportation systems are not designed to segregate bulk, untagged, biotechnology 
agricultural products, on a large scale and with precision, from conventional varieties.”215 
These changes in the storage and transportation structure would place added costs on 
the U.S. farm sector. In addition, according to the State Department, the U.S. govern-
ment “‘does not have the authority to force farmers to market their crop in one channel 
or another. Therefore, the U.S. [g]overnment [cannot] certify that certain varieties are 
completely absent from export channels.’”216 But if this is true in view of the dangers of 
unintended cross-contamination—that biotechnology crops will crossbreed with other 
plants resulting in unintended harmful breeds—the consequences for biodiversity are 
far more severe than simple economic costs, even if the cost of labeling and segregating 
proves to be considerable. If these genetic modifi cations cannot be monitored effectively, 
a more extreme remedy such as a ban may be necessary.
VI. CONCLUSION
The United States should adopt labeling requirements modeled after international 
law, choosing the vigilant approach regarding the use of GMOs in food in light of the 
unknown scientifi c effects and a number of initial harmful results. The point is not that 
all scientists agree, as would never occur, but that there are enough negative implica-
tions with regard to GMOs to question the relatively laissez-faire  U.S. policy. When 
faced with signifi cant scientifi c debate, the U.S. government should err on the side of 
caution, particularly when it involves something as critical as the U.S. food supply. 
That is the position Congress and FDA have taken in the past with food and color ad-
ditives and irradiated food. This apparent inconsistency raises the query, why are these 
governmental units treating this type of food product differently?
In view of the scientifi c uncertainty, risk assessment is essential to determining who 
should bear the risk while identifying and quantifying those risks through responsible 
and appropriate scientifi c methods.217 Particularly when considering the nonquantifi able 
risks, public safety and health considerations should prevail.
A comprehensive system of pre- and postmarket monitoring, enhanced testing, and 
appropriate labeling would realize benefi ts for all stakeholders. Implementing these 
measures would aid consumers by increasing the likelihood of informed decisionmaking, 
industry by increasing the confi dence of consumers, and environmentalists by develop-
ing safety provisions without the need for moratoriums. In addition, by establishing 
standards more consistent with the international scientifi c community for risk assess-
ment and labeling, industry may benefi t from more streamlined and timely approval for 
marketing in the United States with fewer obstacles from abroad.218
215 Stamps, supra note 48, at 7.
216 Id. (quoting U.S. Dep’t of State, Fact Sheet, Frequently Asked Questions About Biotechnology (Jan. 
22, 2001), http://www.state.gov/e/eb/rls/fs/1142pf.hm)).
217 See VED P. NANDA & GEORGE PRING, INTERNATIONAL ENVIRONMENTAL LAW & POLICY FOR THE 21ST 
CENTURY (Transnat’l Publisher 2003) (assessing role of risk analysis); see also Lakshman D. Guruswamy, 
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It is important to recognize that, inasmuch as these issues refl ect cultural differences 
in levels of risk aversion with respect to food and food products, they also involve 
international trade policy and economic concerns beyond matters of science.219 As a 
matter of international trade, the biotechnology industry must “accept the challenge of 
developing and regulating products that take into account regional diverse needs and 
concerns of consumers and specifi cities of the environment.”220
The United States must address these critical environmental concerns and consumer 
demands through legislation and regulation to improve risk management. Only then 
will it be possible for the biotechnology industry to introduce GMOs into worldwide 
markets without signifi cant opposition.221 If neither the U.S. government nor industry 
moves forward to attend to these risks in a meaningful way, increased public aware-
ness and pressure from abroad may further impede international trade and, eventually, 
necessitate a ban of GMOs in the U.S. food supply. Thus, for the sake of the biotech-
nology industry, as well as the consumer, adopting this more cautious approach would 
offer GMOs the most viability in the long run to attain some of the initial promise and 
secure a future in food.
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